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GENETIC ANALYSIS OF THE HIPPO PATHWAY IN MOUSE LIVER
Publication No.
Li Lu
Supervisory Professor: Randy L. Johnson, Ph.D.
Cancer therapy and tumor treatment remain unsolved puzzles. Genetic screening
for tumor suppressor genes in Drosophila revealed the Hippo-signaling pathway as a
kinase cascade consisting of five core components. Disrupting the pathway by deleting
the main component genes breaks the balance of cell proliferation and apoptosis and
results in epithelial tissue tumorigenesis. The pathway is therefore believed to be a
tumor suppressor pathway. However, a corresponding role in mammals is yet to be
determined. Our lab began to investigate the tumor suppression function of the potent
mammalian Hippo pathway by putting floxed alleles into the mouse genome flanking
the functional-domain-expressing exons in each component (Mst1, Mst2, Sav1, Lats1
and Lats2). These mice were then crossed with different cre-mouse lines to generate
conditional knockout mice. Results indicate a ubiquitous tumor suppression function of
these components, predominantly in the liver. A further liver specific analysis of the
deletion mutation of these components, as well as the Yap/Taz double deletion
mutation, reveals essential roles of the Hippo pathway in regulating hepatic
quiescence and embryonic liver development. One of the key cellular mechanisms for
the Hippo pathway’s involvement in these liver biological events is likely its cell cycle
regulation function. Our work will help to develop potential therapeutic approaches for
liver cancer.
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CHAPTER 1: BACKGROUND
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Genetic alteration can cause many human diseases, including developmental
defects in fetus and tumor development in adults. In searching for cures, scientists
have stepped into a long journey of unveiling disease mechanisms starting from
identifying genes that are important for organ development and tissue homeostasis.
These are the two main topics being pursued for decades. With the advances of
research techniques and the discoveries of genetic modification tools, high-throughput
genetic analysis has been established and many genes and pathways essential for
organ development and tissue homeostasis have been identified, one of which is the
Hippo pathway.
At the time we started our project, our knowledge about the Hippo pathway is
limited to Drosophila animal model and the in vitro biochemical interactions between
the mammalian components. For the Hippo pathway’s function in the mammalian
system, although biochemical studies provided valuable information on protein-protein
interactions, they have limitations in addressing how these Hippo pathway main
components function in a true biological environment and how they contribute to the
development or homeostasis of an organ or an animal as a whole. We therefore
generated genetically engineered mouse models of the main components, and started
to investigate the Hippo pathway’s in vivo function in several organs. We later focused
our study on mouse liver because our preliminary data indicated a certain tissuespecificity of the Hippo pathway in liver. We found that deregulation of the Hippo
pathway affected several important aspects of the liver, including inflammatory
response, liver stem cell activation, liver development, and liver regeneration. Our
study will help understand the Hippo pathway’s tumor suppressor function in
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mammals, and may put new insights into the cancer treatments, especially to the liver
cancer treatments.
1.1 Drosophila Hippo pathway
The Hippo signaling pathway was originally identified in Drosophila by genetic
screening for genes involved in cell growth and proliferation. The first identified
pathway component is Wts, whose deletion results in cell autonomous proliferation
and epithelium over growth [1,2]. Warts (Wts) is named for a phenotype in which
mutated cells proliferate dramatically in imaginal discs and grow into wart-like mitotic
clones on adult. Other pathway components were subsequently identified by similar
phenotypes after gene deletion in imaginal discs. These components are: Ste20-like
protein kinase Hpo, WW domain-containing protein Sav, and the adaptor protein Mats
[2,3,4,5,6,7,8,9]. Biochemical studies further put them together as a kinase cassette
(Hpo/Sav1/Mats/Wts): Hpo phosphorylates and activates Wts [8] in the presence of
Sav and Mats that act as scaffolding proteins to facilitate the interaction between Hpo
and Wts. Hpo and Wts are both Ser/Ter kinases capable of being activated by
autophosphorylation [10,11], although Wts activation can also be regulated by Hpo
phosphorylation. Hpo can also phosphorylate Sav and Mats [8,9], which further
facilitates Wts binding and activation. The sequential phosphorylation and activation of
the Hippo pathway components explains the similarity and also the progressive
severity of mutant phenotypes. Deletion of downstream component (Wts) results in a
similar but more severe phenotype than that of an upstream component (Hpo or Sav).
Hpo/Sav/Mats/Wts is the core kinase cassette of the Hippo pathway. It functions to
sense and mediate extracellular signal transduction to the cell nuclei. Although it is yet
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unknown what the extracellular signals are in a normal tissue context, some
intracellular regulators upstream of Hpo/Sav1/Mats/Wts kinase cassette have been
identified, such as Mer-Ex-Kibra complex [12,13,14,15], Fat signaling [16,17,18,19,20],
and Lethal giant larvae (Lgl) complex [21]. Among these regulators, the Mer-Ex-Kibra
complex is the most important, as it activates the Hippo pathway through both Hpo
and Wts phosphorylation. Mer, Ex and Kibra function redundantly in regulating Hippo
signaling pathway and each one can function independent of the others. In the case of
cell-cell contact inhibition, cell will stop growing when the Hippo pathway is activated
by Ex, which is activated by binding with the transmembrane protein Crb upon its
homodimerization between two adjacent cells [22]. This is one of the mechanisms by
which the Hippo pathway regulates cell growth.
Although the Hpo/Sav1/Mats/Wts kinase cassette functions to suppress tissue
growth, none of them is a nuclear transcription factor. By yeast two-hybrid screening,
the nuclear transcriptional cofactor Yki was identified and has been demonstrated to
be a dominant Wts-binding protein. Activated Wts can phosphorylate Yki, and this
phosphorylation enables the binding of an adaptor protein, 14-3-3, with Yki, which is
then followed by Yki cytoplasmic tethering and functional suppression [23,24,25].
While nuclear-cytoplasmic translocation is believed to be the main mechanism of
regulation for Yki function, there is also evidence that Wts can inhibit Yki through
physical binding [23]. This finding further explains why the Wts deletion has the most
severe phenotype compared to the deletion phenotypes of other the Hippo pathway
components. Yki activity can also be suppressed by direct protein-protein binding
between its WW-domains and the proline-rich sequences within PPXY motifs. This is
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evidenced by Yki inhibition in association with Ex, Kibra, Hpo or Wts [26,27], all of
which have the PPXY motifs. Although several Hippo pathway upstream regulators
have been identified, Yki is so far the only known nuclear effecter of the Drosophila
Hippo kinase cassette that bridges the cytoplamic Hpo/Sav1/Mats/Wts kinase cassette
with nuclear target gene transcription.
Yki itself lacks a DNA binding domain. It has to associate with DNA-binding
proteins to execute its gene transcription regulation function. Several associated
transcription factors have been identified, such as Sd (initiates diap1 gene expression)
[28,29], Mad [30] and Hth [31] (for ban expression). dE2F1 can also associate with Yki
and function synergistically with the Yki/Sd complex in promoting G1-to-S phase cell
cycle progression [32]. This supports the notion that the Hippo pathway regulates cell
cycle and proliferation and thus controls tissue growth.
In summary, Hpo/Sav1/Wts/Mats kinase cassette mediates signal transduction of
extracellular stimuli down to the nuclear transcription cofactor Yki. The diverse
transcription factor binding ability of Yki enables the Hippo pathway to function in
multiple biological processes. The observations that deletion of any component in
Hpo/Sav/Wts/Mats cassette or over-expression of Yki results in tissue over-growth and
organ enlargement suggests that the Hippo pathway plays fundamental roles during
organ size control and may also be a suppressing pathway during tumorigenesis, an
uncontrolled cell proliferation process (Diagram 1).
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Diagram 1. Drosophila Hippo pathway. Hpo kinase is activated by Mer/Ex/Kibra
complex). Activated Hpo kinase phosphorylates and activates kinase Wts, which is
facilitated by Sav adaptor protein. Activated Wts, with another helper protein Mats,
phosphorylates the nuclear transcription cofactor Yki. This phosphorylation, however,
inhibits Yki function. Unphosphorylated Yki will associate with transcription factors,
such as Sd, to initiate target-gene expression, some of which are known to be proproliferation and against apoptosis.

6

1.2

Mammalian counterparts of the Hippo pathway components.
The Hippo pathway is evolutionarily conserved. Many core components exist

across species, including yeast, flies, rodents, and Homo sapiens. Most mammalian
counterparts have functionally redundant paralogs as shown in Table 1. Biochemical
interactions among mammalian counterparts are similar to those in Drosophila
(Diagram 2) [8,9,23,33,34,35]. Briefly, Mst phosphorylates and activates Lats which
further phosphorylates Yap/Taz. Phosphorylated Yap/Taz binds to adaptor protein 143-3 and is exported from the nucleus [35]. Sav1 and Mob1 function to facilitate the
interaction between Mst and Lats.
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Table1. Mammalian counterparts of the Hippo pathway core components
Drosophila

Mouse/Human

References

Mst1
Hpo

[36,37,38,39,40,41]
Mst2

Sav

WW45/Sav1

[42]

Lats1
Warts

[43,44]
Lats2

Mats

Mob1

[45,46,47]

Yap
Yki

[34,48,49,50,51]
Taz/WWTR1
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Diagram 2. Biochemical interactions between the mammalian Hippo pathway
components. Lats1/2 (Wts orthologs) can be activated through phosphorylation by
Mst1/2 and Kibra/NF2 (Mer ortholog) complex, both of which are facilitated by the
adaptor protein Sav1 (Sav ortholog). Activated Lats1/2 further phosphorylates but
inhibits Yap/Taz (Yki ortholog), which is facilitated by another adaptor protein Mob1.
Unphosphorylated Yap/Taz associates with the transcription factor TEAD and initiates
the target gene expression, such as ctgf.
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Mst1 and Mst2 are Ste20-like kinases that ubiquitously expressed. The Cterminal SARAH domain mediates Mst1 and Mst2 self-binding and also binding with
other SARAH-containing proteins such as Sav1 and Nore1 (a member of the Rassf
tumor suppressor family). The Mst /Sav1 complex functions as mammalian Hippo
signaling that inhibits growth. Mst/Nore1 complex plays an important role during T-cell
development. Mst inhibitory effect on cell growth and survival is also represented by its
involvement in stress-induced cell apoptosis, during which Mst is activated by
caspase-dependent cleavage into a 36 kDa protein kinase which translocates from the
cytosol to the nucleus where it contributes to chromatin condensation during apoptosis
[52]. Overall, Msts exert a negative effect on cell growth and survival.
Lats belongs to the NDR/Lats kinase family and was known to be a tumor
suppressor before it was related with the Hippo pathway. Lats expresses ubiquitously
and plays essential roles in various cellular events such as proliferation, cytoskeletal
dynamics, cell migration, mitotic exit, transcriptional regulation and genetic
maintenance of stability maintenance [53]. The multiple functions rely on its protein
structure, which contains a protein-binding domain (PBD), a catalytic domain, two Lats
conserved domains (LCD), and PPxY motifs. Lats potentially interacts with multiple
cellular regulators and is thought to be a broad governor for cellular homeostasis.
However, so far Yap and Taz are the only two identified substrates of Lats.
Sav1 (also named WW45) and Mob1 are scaffold proteins that facilitate
interaction between Mst-Lats and Lats-Yap/Taz, respectively. Sav1 biochemically
binds to Mst1, Mst2 and Rassf1 [54,55]. It has two WW-domains, which can bind to
PPXY motifs within other proteins including Lats and Yap/Taz. Evidence shows that
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NF2 (Mer ortholog) together with mammalian Kibra can phosphorylate and activate
Lats by binding with Sav1 [56]. Therefore, functions of mammalian Sav1 are thought to
be very similar to its Drosophila ortholog. Mob1 is known to be required for the
abscission of the midbody during cytokinesis. Other than this, little is known about
Mob1.
Both Yap and Taz are mammalian orthologs of Yki, with Yap being more
structurally similar to Yki. Yap has two WW-domains while Taz has only one [57]. Taz
lacks an SH3-domain, which is present in Yap. The structural difference suggests that
Yap but not Taz may be the predominant effecter of the mammalian Hippo pathway.
Like Yki, both Yap and Taz lack a DNA binding domain, and must be associated with
transcription factors to regulate target gene transcription. Computational prediction,
based on domain-domain interaction, has identified many transcription factors as
potential Yap/Taz associating-proteins, some of which are already known to be
important for cell cycle regulation such as C/EBP and P73. The predicted transcription
factor TEF/TEAD has been demonstrated to associate with Yap/Taz [58,59,60] and
initiate ctgf gene expression [61,62]. Ctgf is required for chondrocyte proliferation,
angiogenesis, extracellular matrix production and turnover. Moreover, Yap and Taz
have distinct partners that regulate expression of different sets of target genes. For
instance, Taz interacts with TBX5 [63] and Smad2/3/4 [64], while Yap interacts with
ErbB4 [65] and Smad7 [66]. Both Yap and Taz can be phosphorylated and inhibited by
Lats. They are the only two identified effectors of the mammalian Hippo signaling
pathway.
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1.3

Liver function and liver development
The liver is the largest solid organ of the body and has essential functions in

metabolism, detoxification, and biosynthesis. It is located in the upper right-hand
portion of the abdominal cavity, beneath the diaphragm and on top of the stomach and
intestines. Nutrients (carbohydrate, fat and protein) from the intestine are further
digested in the liver and the products are converted into other energy forms (protein,
glucose, vitamins, etc.), which can be either stored or released into blood to meet body
consumption. It also filters body wastes (bilirubin, ammonia) and toxins (alcohol, drugs
and chemicals) from blood and transforms them into either water-soluble or bilesoluble materials for elimination through kidney or as feces, respectively. Therefore,
liver functions as a guardian to keep the body healthy.
The major cell type of the liver is the hepatocyte, which constitute about 70% of
the whole liver mass and are the main cell type that performs liver function [67]. The
remaining 30% of cells are non-parenchymal cells, including BECs (Biliary Epithelial
Cells, also called cholangiocytes), stellate cells, küpffer cells, and sinusoidal
endothelial cells. Hepatocytes and BECs are epithelial cells that are derived from
embryonic endoderm, while the other cells are from embryonic mesoderm. The
development of the liver is a consequence of reciprocal tissue interactions between
endoderm and nearby mesoderm. It originates from the ventral foregut endoderm
around embryonic day 8.0 (E8.0) of gestation [68,69]. Hepatic diverticulum forms
around E9.0 when it is adjacent to the developing heart. At E9.5, the hepatoblasts
(progenitor cells of both hepatocytes and BECs) delaminate from the anterior portion
of the hepatic diverticulum and invade the adjacent mesenchyme to form the liver bud
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[70,71,72]. The reciprocal interactions between endoderm and mesoderm promote
hepatoblast proliferation and stellate cell formation from the adjacent mesenchyme
[73,74,75,76]. Between E10.5 to E15, the liver bud grows tremendously due to
hepatoblast proliferation and latter on differentiation. Biliary epithelial cells emerge
early on E11.5 [77] adjacent to the portal vein, and keep on differentiating and growing
while interacting with adjacent endothelial cells and mesenchymal cells. Majority of the
hepatoblasts differentiate into hepatocytes. The process continues untill the
characteristic architecture of the liver comes into being, which is around birth.
Several signaling pathways are known to be important for BEC development and
bile duct formation, such as TGFβ signaling, Wnt signaling, and Notch signaling
(Diagram 3). TGFβ signaling forms a gradient with a higher level in the portal region
and a lower level in the parenchymal region [78,79]. This gradient is important for
biliary differentiation as evidenced by suppression of biliary differentiation following
TGFβ pathway blockage, and ectopic biliary differentiation following TGFβ pathway
activation. Wnt signaling is temporally activated during biliary differentiation, peaking
around E12.5 but completely being suppressed after E16.5 [80]. Notch signaling
(Diagram 4) promotes biliary differentiation and is activated specifically in the portal
region by its ligand jagged1, which is secreted from portal endothelial cells [81,82,83].
This also explains why the bile ducts only forms close to the portal vein. This
interaction between the portal hepatoblasts and the endothelial cells is essential for
bile duct development. In human, Jagged1 mutation is responsible for an autosomal
dominant disorder called Alagille syndrome (AGS) [84,85,86]. Jagged1 and Notch2
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deleted mouse mimics the human AGS symptom, and therefore being used as a
model for the study of bile duct development [81,82,87,88,89,90,91].

Diagram 3. Molecular signals regulating the bile duct development. The development
of the bile duct can be roughly divided into two steps: the BEC fate determination, and
the tubular morphogenesis. Some known factors that contribute to the fate
determination step are the Notch signaling, TGFβ and Tbx3. While Notch and TGFβ
promote BEC differentiation from hepatoblast, Tbx3 inhibits the process. Notch and
TGFβ also play a role during the tubular morphogenesis. Notch activates several
targets genes that are important for the tubular morphogenesis, such as HNF1β, Hes1
and Sox9, making it to be a major signaling that regulates the bile duct tubular
morphogenesis.

14

Diagram 4 Notch signaling. Notch signaling is activated via the binding of Notch transmembrane receptor with ligand Jagged1 or DLL (Delta-like ligand) from adjacent cells.
The Notch intracellular domain (ICD) is then cleaved by γ-secretase and translocates
into the nucleus, where it binds to Recombination signal-binding protein (RBP) and
initiates Hes and Hey genes expression.
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The characteristic architecture of the adult liver is the liver plate. In human and
swine, the liver plate is lined up by connective tissues and segregated into a hexagon.
However, murine liver plate is not clearly segregated by connective tissues, although it
consists of similar anatomic structures: portal triads and a central vein (CV) (Figure. 1
and Diagram 5). A portal triad consists of a portal vein (PV), a bile duct and a hepatic
artery. The hepatocytes line up as cords connecting the central vein with portal triads.
Between the cords are sinusoids that are lined up with endothelial cells. The major
liver immune cells, Küpffer cells, reside in the sinusoids. Between the hepatocytes and
the endothelial cells is the space of Disse where the hepatic stellate cells reside.
Following liver injury, stellate cells can be activated and secrete collagens that
contribute to liver fibrosis and cirrhosis [92]. Liver architecture is important for proper
liver function and liver homeostasis. Nutrients and biochemical materials from the
small intestine enter into liver through the portal vein, and then together with blood
from hepatic arteries pass through the sinusoids and empty into the central veins. On
the other hand the bile acids secreted by hepatocytes are collected in hepatic
canaliculus and flow towards bile ducts. The two flows ensure efficient nutrition
transportation and biological material recycling between liver and intestine. Under
some disease conditions, when liver architecture is disrupted by infiltrating immune
cells or activated liver stem/progenitor cells, the blood and bile acid flows will be
perturbed and the resulting hepatic injury may elevate the disease status to tumor
development.
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Figure 1. Normal adult mouse liver plate and portal triad structure. (A) HE staining
shows typical mouse liver plate structure: central vein (CV) and portal vein (PV)
surrounded by hepatocytes. (B) is a higher magnified view of the portal triad as
squared in (A). Green arrow points to a bile duct and yellow arrow points to a hepatic
artery.

Diagram 5 Cell types and functional structures of the liver.
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1.4 Liver cancer
Liver cancer is the third leading cause of cancer-related patient death. The 5-year
survival rate of patients with liver cancer is less than 10%. Additionally, over 50% of
liver cancer patients have cancer recurrence within 3 years after tumor removal
surgery [93,94]. This high mortality is due to both the lack of early diagnosis and the
quick malignant aggressive nature of liver cancer [95]. Adult primary liver cancer is
highly associated with HBV and HCV infection which induces chronic inflammation,
parenchyma regeneration and subsequent liver cirrhosis, dysplastic lesions and
eventually liver carcinomas [96]. Heavy alcohol abuse and corrupted food intake can
exacerbate disease severity [97]. Liver stem cell and progenitor cell activation due to
viral infection, chronic inflammation and cirrhosis can potentially lead to malignant
transformation.
Based on the cellular origin, there are two types of primary liver cancers: the
hepatocellular carcinoma (HCC) and the cholangiocarcinoma. HCC features
uncontrolled hepatocyte proliferation and cytoplasmic content decrease. The
cholangiocarcinoma is characterized by the expanding of poorly organized bile ducts
due to bile epithelial cell proliferation. The two types of carcinoma cells sometimes coexist within one liver tumor, which is believed to be originated from common liver stem
or progenitor cells which possess dual differentiation abilities into both hepatocytes
and cholangiocytes (bile ductal cells, biliary epithelail cells) [98]. Tumors with cancer
stem cells are malignant and frequently relapse after treatment [98,99,100,101].
Understanding the roles of cancer stem cells during tumorigenesis may help improve
liver cancer treatment. Liver stem cells are believed to reside in the bile ducts or the
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periportal area. However, there has been no specific biomarker to identify them. The
identification of liver stem cells relies on their morphology of an oval shape (so called
oval cells) which can be determined by electron microscopy [102]. By using this
technique, several intermediate progenitor cell types between oval cells and mature
hepatocytes are identified and classified as Type I, II and III hepatic progenitor cells.
The rare oval cells are termed as Type 0 cells [102]. In liver disease models, such as
allyl alcohol-induced hepatic necrosis in rat, the activated periportal cell expansion
always consists of mixed cell populations of the abovementioned cell types. Since
more differentiated cell types (like Type II and Type III) appear at later stage and more
undifferentiated progenitor cells (like Type 0 and Type I) appear at early stage, a
scheme of dynamic cell differentiation from Type 0 to Type III and finally hepatocytes
can be illustrated [102]. The available antibodies such as OV-6, A6, OC2-1D11 and
MIC1-1c3 [103] can only recognize a mixture of these cell types but not a designated
one.
1.5 Organ size control
Organ size can be determined by the cell number as well as the cell size [104].
For example, an elephant heart is bigger than a mouse heart is because it has more
cells [105], whereas a small wing of some Drosophila strain is a result of smaller cell
size [106]. A certain organ’s size, however, is determined at a level of the total organ
mass, which is achieved by coordinately regulated cell number and cell size. A good
example is that although a tetraploid salamander has twice the cell size of that in a
diploid salamander, the corresponding organs’ sizes are similar in the two animals
because the tetraploid salamander has half cell number of the diploid salamander’s
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[107]. Also, changes in cell number from deregulated cell proliferation do not
necessarily result in changes in organ size [108,109]. These experimental findings
suggest that there is a “total mass setting point” mechanism, which functions to link the
regulation of cell number (proliferation) and cell size (growth).
In the studies of the “total mass setting point” mechanism, genetic screening has
been carried out in Drosophila looking for genes whose mutations can decouple the
cell number - cell size regulation and result in dramatic organ size changes. The
insulin-signaling pathway was identified to be an important organ size control pathway
in that it regulates cell growth without affecting cell proliferation (reviewed in [110]).
Mutations of its components often affect cell growth and consequently change cell size
only and result in changes in organ size. It functions through PI3K/AKT pathway and
regulates mRNA transcription as well as protein translation. The consequence is the
change in RNA:DNA ratio and protein amount, which contributes to the change of cell
size [111]. The size control mechanism by the insulin pathway has been further
confirmed in mammalian system: in mouse heart, increase or decrease the activity of
this pathway results in a corresponding heart size change, and this change is
associated with comparable increase or decrease in myocardiocyte size [112]; in
mouse liver, transient activation of the insulin pathway by activation of Akt triggers a 34-fold liver size increase within days due to hepatocyte hypertrophy without significant
hepatocyte proliferation [113]. The importance of insulin pathway in determining the
“total mass setting point” is further supported by data from liver regeneration
experiments, in which it compensates hepatocyte proliferation deficiency through
promoting cell growth [114,115]. The most striking phenomenon is that disrupting PI3-
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K/PDK1/Akt pathway, the main cytoplasmic kinase complex of the insulin pathway,
does not affect hepatocyte post-PH mitotic response, rather, significantly ceases liver
regeneration due to the inability of cell growth [115]. These findings supports that the
insulin-signaling pathway is a conserved organ size control pathway, and it plays
important roles in the “total mass setting point” mechanism through regulating cell
growth/size.
The recent identified Hippo pathway has been also connected to organ size
control mechanism. However, instead of regulating cell growth, the Hippo pathway
appears to be important for cell number regulation by balancing cell proliferation and
apoptosis. Deregulation of the Hippo pathway in Drosophila results in overgrowth of
the imaginal discs and enlargement of the corresponding adult organs without
affecting cell size and tissue patterning (reviewed in [116]). Several identified Hippo
pathway target genes are related with cell cycle progression (bantam, cyclin E) and
cell survival (diap1), suggesting a role of the hippo pathway in cell number regulation.
However, whether the Hippo pathway is a conserved organ size control pathway in
different species and contributes to the “total mass setting point” mechanism needs
further investigation.
Studying the mechanisms in organ size control is important not only because the
organ size control is a fundamental biological question, but also because the potential
genetic linkage between this mechanism and tumorigenesis. Genes contributing to the
insulin pathway, the known organ size control pathway, are often mutated in
tumorigenesis. PTEN affects organ size through negatively regulates cell size
[117,118,119]. It negatively regulates the insulin signaling and is one of the most
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frequently mutated genes in many types of human tumors [120]. Tuberous sclerosis
complex
(TSC), another component of the insulin pathway, is a tumor suppressor [121], whose
mutation results in Drosophila eye enlargement due to the dramatic increase in cell
size [122]. Exploring the organ size control mechanism may help to better understand
tumorigenesis.
1.6 Liver regeneration
The liver is a unique organ that maintains its regenerative ability throughout its
lifetime [123]. Liver regeneration can be triggered by hepatocyte injury (toxin intake) or
hepatic tissue loss (hepatectomy) [124]. While toxins often induce liver inflammatory
responses and progenitor cell expansion in addition to hepatocyte proliferation,
surgical resection only induces hepatocyte proliferation. Therefore using surgical
resection to induce liver regeneration is widely used in studies of liver regeneration. In
addition, the reproducibility of partial hepatectomy (PH) in terms of liver mass removal
and the precision of ensuing event timing have made PH a preferred approach for
experimental liver regeneration study [125,126].
Full liver re-growth by surgical induced liver regeneration takes about 7-10 days
in rodents. The whole process is characterized by a synchronous induction of normally
quiescent hepatocytes to reenter the cell cycle, which leads to a complete restoration
of liver mass [127]. The major cellular events can be briefly divided into three phases:
the priming phase (0h-12h after PH), the proliferation phase (12h-72h after PH), and
the growth termination phase (72h-7 days after PH) [128]. Right after PH (priming
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phase), the non-paranchymal cells (mainly the Küpffer cells and stellate cells) are
activated and secrete cytokines (e.g. IL-6) and growth factors (e.g. HGF) to induce
hepatocyte proliferation (proliferative phase). The initiation of hepatocytes cell cycle
reentry is a complicated process and requires the activity of multiple pathways, which
also link to each other in some way and function in a redundant manner. One wellknown signaling that activates hepatocyte proliferation is the IL-6 -Jak-Stat pathway.
IL-6 accounts for about 40% of the immediate early genes in the priming stage
[129,130] and IL-6 KO mice show striking deficit in DNA replication after PH [131]. IL-6
signaling can activate cell cycle regulators, such as Cycin D1, a hall maker for
hepatocyte cell cycle reentry. Increased expression of Cyclin D1 activates Cdk4/6,
which promotes hepatocyte G0-G1 transition. The importance of Cyclin D1 in
hepatocyte cell cycle reentry is affected by: transient expression of cyclin D1 is
sufficient to initiate hepatocyte proliferation [132,133]; diminished expression of Cyclin
D1 is related with impaired liver regeneration [131,134]. Another important factor that
regulates hepatocytes cell cycle re-entry is P21, which is a universal Cyclin kinase
inhibitor and promotes cell cycle exit [135]. Liver regeneration impairment resulting
from blockage of the G1/S transition can be restored by P21 deletion [136], suggesting
P21 plays an pivotal role in suppressing G1/S transition. P21 expression peaks around
24 hours after PH, when hepatocytes begin to exit the cell cycle. The termination
phase mainly involve extracellular matrix synthesis and reestablishment, hepatocyte
and bile duct rearrangement [128]. Complete liver function recovery is around 14 days
after PH.
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Our lab investigated the Hippo pathway function in vivo by generating conditional
knockout mice for each main component and analyzing the phenotypes of these
mutant mice. We found that the Hippo pathway is important for liver homeostasis and
tumor suppression. In addition, it may contribute to liver development through
controlling the BEC differentiation. Finally, it is not a critical pathway for the “total mass
checkpoint”-organ size control mechanism; however, it does play an important role in
regulating hepatocyte cell-cycle reentry during the liver regeneration. Our study is
among the first ones to address these questions, and the results may help understand
the molecular mechanisms of fetal liver development and adult liver homeostasis.
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CHAPTER 2: RESEARCH RATIONALE
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We hypothesized that the Hippo pathway is a tumor suppressor pathway as well
as an organ size control pathway in the mammalian system according to its function in
Drosophila and the conservation of the components in mammals. In Drosophila,
deregulation of the Hippo pathway kinase cassette and up-regulation of its nuclear
effecter Yki causes cell uncontrollable proliferation and organ tumor-like growth. In
addition, dysregulation of the Hippo pathway in Drosophila decouples the cell
proliferation and cell growth in imaginal discs and leads to adult organ size
enlargement. The two topics are related in that organ size control is one of the
mechanisms for maintaining tissue homeostasis.

2.1 Role of Hippo pathway in mouse liver tumorigenesis.
Genes that affect cell proliferation or growth can be oncogenes (e.g. myc
[137,138]) or tumor suppressors (e.g. p53 [139,140], pten [120]). In human,
dysregulation of the Hippo pathway main components in tumor tissues has been
reported. Yap and Taz are abnormally expressed in a variety of human cancers,
including colonic adenocarcinoma, lung adenocarcinoma , ovarian serous
cystadenocarcinoma, HCC, and breast cancer [50,141,142]. Decreased expression of
Mst1 and Mst2 due to promoter hypermethylation has been reported in soft tissue
sarcomas, which suggests their potential roles as tumor suppressors [40]. Mst can be
activated by forming a heterodimer with members from the tumor suppressor family of
Rassf [55] whose expression is often inactivated by epigenetic silencing in human
cancers. Given that the Rassf family has at least six members and they do not exist in
Drosophila, we can assume that the mammalian Hippo signaling pathway could have
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distinct and complicated regulatory mechanisms. Sav1 deletion in human cancer is
rare and has only been reported in one colon cancer and two renal cancer cell lines
among 52 cancer cell lines [42]. Lats1 and Lats2 are believed to be broad governors of
cellular homeostasis. Their deregulations have been reported in astrocytoma [43],
breast cancer [44], leukemia [143], soft tissue sarcoma [144], lung cancer [145] and
prostate cancer [146]. Taz is required for kidney and lung organogenesis [147] and
breast cancer stem cell quiescence [141,148]. We therefore hypothesized that the
Hippo pathway is a tumor suppressor pathway in mammals, and we used several
genetically engineered mouse models to test this hypothesis. Uncontrolled cell
proliferation and tissue overgrowth are features of tumorigenesis.
The mammalian Hippo pathway is complicated by the paralogs of the main
components as they potentiate more regulatory interaction with other factors. Null
mutations of the major components of the Hippo pathway have been generated, and
results revealed significant functional redundancy between the paralogs. Mst1 or Mst2
deficient mice are relatively normal. But Mst1 and Mst2 double deficient embryos die
around E8.5 due to hematopoietic defects [149], suggesting a strong functional
redundancy between Mst1 and Mst2. Sav1 is also required for embryonic development
because its germline deletion causes embryonic lethality at around E17.5 to E18.5 due
to defects in placenta vascularization [150]. Lats1 null mice are viable but lack
mammary glands. They are infertile, exhibit growth retardation, and develop soft tissue
sarcoma and ovarian tumors [151]. Lats2 null mice show a more severe phenotype as
they die before E12.5 and also exhibit growth retardation [152]. Both observations
suggest that Lats1 and Lats2 have distinct functions and are both required for
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embryonic development. The earlier embryonic lethality of Lats1/2 double deleted
mutants (unpublished data) implies that functional redundancy exists between Lats1
and Lats2. Yap-null mice die around E8.5 with defects in yolk sac vasculogenesis,
chorioallantonic fusion, and body axis elongation [153]. Viable Taz null mice have
defects in the kidney [147,154]. On the other hand, potential functional redundancy
and a possible synergistic relationship between Yap and Taz are reflected by the
observation that Yap/Taz double null embryos die before the 16-cell morula stage
[155]. Embryonic lethality hinders further analysis for the potential tumor suppressor
function of this pathway in adults, and therefore gene conditional deletion in adult
tissues is required. The dissection of how the Hippo pathway contributes to tissue
homeostasis and tumorigenesis in the adult is important for uncovering its role during
human tumorigenesis and providing valuable information for cancer treatment.
The Cre/Loxp recombination system is the most commonly used conditional gene
deletion strategy. By crossing the mice bearing loxp-flanked allele(s) in the functional
domains of the target genes with the mice bearing either tissue specific promoterdriven cre or tetracycline-inducible cre, we generated series of tissue-specific/inducible
conditional gene knockout mice. Defects were seen in mammary glands terminal end
bud (TEB) cell differentiation (Figure 2A), intestinal villus development (Figure 2B),
brain, liver, ovary, and testis epididymis (data not shown). Although the Hippo pathway
is involved in the development of almost all examined tissues, the liver seems to be
the most susceptible organ to the Hippo pathway deficit. Low-frequency gene deletion
of Mst or Sav1 in the liver (as evidenced by low and scattered cre expression driven by
non-liver specific MMTV [156] and CAGGS [157] promoters) led to liver tumorigenesis.
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Our finding is consistent with the previous report about Yap overexpression resulting in
liver cancer [34]. The dramatic phenotypes from altered expression of Hippo pathway
components make liver an ideal organ model for studying the in vivo function of this
pathway. In addition, this study also has clinical significance. In a study consisting of
177 patient liver tumor biopsies, 62% of them show Yap over-expression and nuclear
accumulation, which significantly correlate with poor differentiated tumor cells. Yap
nuclear accumulation correlates with tumor relapse after tumor resection and low 5year patient survival rate [51], which makes Yap become a new prognostic marker for
HCC. Therefore, figuring out how the Hippo pathway regulates Yap activity and
contributes to the tumorigenic process may help to develop therapeutic approaches for
liver cancer.
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Figure 2. Sav1 deletion in mammary gland and Mst1/2 deletion in intestine. (A) On
18th day of mice pregnancy, wild type TEB cells differentiate into milk-secreting
alveoli, which are large and plump; but the MMTV-cre;Sav1 TEB cells do not
differentiate well. The mutant alveoli are small and do not contain much milk as
compared with the wild type. (B) In intestine, the wild type duodenum has well
developed and organized villi and crypt layers, whereas the villin-cre;mst1/2
duodenum has thinner basal layer and disorganized crypt layers, together with
massive cell vacuolation.
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To specifically analyze how the Hippo pathway kinase cassette (Mst/Sav1/Lats)
regulates Yap/Taz function in the liver, we used alb-cre to delete the Hippo pathway
genes in all (>90% [158]) hepatocytes, as well as in the BECs. The alb-cre mouse line
has been widely used for liver-specific gene knockout studies. The albumin promoter
activates around E9.5 [159]; however, 90% gene deletion will not be achieved until
after birth [158]. In this manner, alb-cre mediated gene deletion occurs in both
hepatocytes and BECs in a developed liver, and the deletion in the embryonic liver is
mosaic. Alb-cre mediated gene deletion usually does not cause embryonic lethality,
except if the interested genes are essential for liver function. An example is C/EBP, an
important transcription factor for liver energy homeostasis [160].
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2.2 Role of Hippo pathway in mouse liver regeneration
In Drosophila, deregulated Hippo pathway results in overgrown imaginal discs
and corresponding increase in adult tissue due to enhanced cell proliferation and
reduced cell apoptosis. Change of cell size is not found, and the overgrown tissues still
maintain normal patterns. Hippo pathway is thus linked to an organ size control
mechanism and, unlike the insulin pathway, it may contribute to the “total mass setting
point” mechanism by regulating cell number without affecting cell size.
Similar phenomena have been observed in the mammalian system. Enlarged
heart [161] and liver [34,37,38,41] sizes due to uncontrolled cell proliferation have
been observed when the Hippo pathway is deregulated. In mouse liver, the hepatocyte
number but not size shows a correlation with Yap amount: liver size dramatically
enlarges when Yap over-expression is induced to promote hepatocyte proliferation;
whereas the liver shrinks towards its normal size due to hepatocyte apoptosis when
withdrawing the induction [34]. Pro-proliferation and anti-apoptosis are also observed
in Mst mutants [41]. However, whether these phenomena are the consequences of the
disturbed organ size control mechanism or just a disease symptom need to be
clarified.
Previous reports about liver size control suggest that the liver size is well
regulated by complicated signaling networks and the majority of gene deletions only
impair rather than totally cease the liver regeneration. For example, myc functions to
promote cell proliferation and is activated during the priming phase of liver
regeneration [162]. However, Myc deleted liver still can regenerate and grow back to
its original size [163,164], implying its function can be compensated by other liver size
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control mechanism. However, whether and how much the Hippo pathway accounts for
liver size control needs to be further investigated.
Liver size setting point is recognized to be 4~5% of the host’s body weight, and it
is strictly regulated throughout lifetime by liver’s unique regeneration ability.
Theoretically the liver regeneration is regulated by the size control mechanism, and
any deficit in liver regeneration should reflect disturbances of the size control
mechanism. We used partial hepatectomy (PH) technique to induce liver regeneration
to test our hypothesis. The benefits of using PH to induce liver regeneration are: first,
the PH technique has been well established [165] and extensively studied
[128,166,167,168], which technically ensures the project’s performance. Second, PH
induced liver regeneration is a process of synchronized hepatocyte proliferation with
well defined timing of cell cycle events, which eases the analysis by providing plenty of
samples for any regeneration phases. Third, PH induced liver regeneration is a normal
biological phenomenon happened in an mature organ, therefore excluding the
signaling interferences from developmental process or disease effect.
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CHAPTER 3: MATERIAL AND METHODS
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3.1 Breeding and generation of mice with sav1 deletion, mst1;mst2 double deletion,
lats1;lats2 double deletion, and Yap;Taz double deletion
Sav1 fl/fl, mst1 fl/fl, mst2 fl/fl, lats1fl/fl, and lats2fl/fl mice were designed and generated
by Randy Johnson (PhD, MD Anderson Cancer Center). These mice have a mixed
genetic background of C57BL/6, 129SvEvTac and CD1. Yapfl/fl and tazfl/fl mice were
design and generated (but not published) by Eric Olsen’s lab (PhD, UT Southwestern
Medical Center, Dallas, TX). Yapfl/fl;tazfl/fl mice were bred with our mouse colony, and
therefore they also have a mixed genetic background. Sav1fl/fl, mst1 fl/fl, mst2 fl/fl mice
were subsequently bred to alb-cre, MMTV-cre, villin-cre and CAGGS-creER(T2) mice
followed by backcrossing to homozygous floxed animals. Lats1fl/fl, lats2fl/fl, yapfl/fl;tazfl/fl
were bred to alb-cre mice followed by backcrossing to homozygous floxed animals.
All mice were housed in a conventional facility with a 12-h light/dark schedule and
access to food and water ad libitum. All procedures were approved by the University of
Texas, M. D. Anderson Cancer Center Animal Care and Use Committee.

* “fl/fl” will be omitted in the following paragraph. For example, “alb-cre;mst1/2”
represents “alb-cre; mst1 fl/fl; mst2 fl/fl ”.
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3.2 Genotyping
Genotype of each mouse was analyzed by PCR. Chromosome DNA was
extracted from tail lysate from 2~3 weeks old mice using previously described
techniques [169,170,171]. Primers (Table 2.) were designed to detect the floxed exon
in each gene. The PCR conditions were 35 cycles of 95°C for 30 seconds, different
annealing temperatures (Table 2.) for 30 seconds and 72°C for 1 minute. PCR
products were run in agarose gel added with ethidium bromide. Genotypes were
determined according to specific bands (Table 3.)
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Table 2. Primer information
Gene

Primer sequcence (5’ – 3’)
F

CCTGCTTCAGTGTTGGCTCTTGATTTTCCT

R

TAGACCAGCCAGGGCTAGAGTGAAACCTTG

F

GTTCAGGGTCCCACCAAGAGTCGCTTCATT

R

TGTCTAGCTGCTGATGACACTGAACTTCTGGC

F

TGTCAGTGTAAAATGGCCACA

R

TTGGGAATGGTTTTACAAGTTT

F

TTGTTGCTGGTGTTGTTTCC

mst1

50

mst2

55

sav1

50

lats1

55
R

ATGAATGAACCTGAGGCTGC

F

ATCCTAGCACTCAGGAGGCA

R

ACACATTCCCCTCCACTGAC

F

ACATGTAGGTCTGCATGCCAGAGGAGG

R

TGGTTGAGACAGCGTGCACTATGGAGC

F

GGCTTGTGACAAAGAACCTGGGGCTATCTGAG

lats2

55

yap

taz

A.T. (°°C)

60

62.5

37

R

AACTGCTAACGTCTCCTGCCCCTGACCTCTC

F

TCCAATTTACTGACCGTACACCAA

cre

55
R

CCTGATCCTGGAATTTCGGCTA

F: forward primer
R: reverse primer
A.T. : Annealing Temperature
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Table 3. PCR product size
Gene

Allele

PCR product size (bp)

Wild type

319

loxP

400

Wild type

213

loxP

370

Wild type

250

loxP

405

Wild type

182

loxP

350

Wild type

235

loxP

380

Wild type

457

loxP

600

Wild type

496

mst1

mst2

sav1

lats1

lats2

yap

taz

39

cre

loxP

655

cre

450
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3.3 Tissue processing and paraffin slides preparation
Mice were sacrificed by cervical dislocation. Liver tissues were cut into 5 mm-thick
pieces and fixed with 4% PFA overnight at 4°C. The next day, the fixative was washed
off with PBS, and then the tissues went through increasing alcohol gradient (70%90%-100%). After dehydration, tissues were cleared in Xylene for 45 minutes and then
put into 65°C liquid paraffin for over 6 hours with three times paraffin change. Lastly,
the tissues were put into metal cassette and embedded in paraffin by cooling down to
4°C. Paraffin blocks were cut into 5 µm sections and slides were put on 37°C heater
overnight to ensure tissue attachment.
3.4 Immunostaining with paraffin slides
Slides were pre-heated in 65°C oven for 1 hour to melt the paraffin and also
enhance tissue attachment. They were then deparaffinized in 3 changes of Xylene
with 15 minutes in total, followed by rehydration in decreasing alcohol gradient until
into water (100% - 90% - 70% - ddH2O). Heat antigen retrieval was carried out in
sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, PH6.0) for 15 minutes
using a steamer. After cooling down for 20 minutes, the antigen retrieval buffer was
washed off with PBS for 5 minutes and three times. Endogenous biotin was blocked by
putting the slides into 3% H2O2 (in Methonal) for 15 minutes, followed by antibody
blocking with 5% normal horse (or goat) serum for 1 hour at room temperature. After
that, slides were added with primary antibody (Table 2) and incubated in a wet
chamber at 4°C overnight. The next day, after washing off the primary antibody with
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PBST, 5 minutes for 3 times, tissues were incubated with HRP or fluorescence
conjugated secondary antibody for 1 hour at RT. The positive staining signal was
developed with DAB reagents (Vector Laboratory, SK-4105). The tissues were
counter-stained with Mayer’s hematoxylin (Fisher Scientific, TA060MH), and then
dehydrated in increasing alcohol gradient into Xylene. Slides were then sealed with
Permount (Fisher Scientific, S70104) and signals were detected with microscope
under bright field.

* note: For fluorescent staining, seal the slides with anti-fade mounting solution
with DAPI (invitrogen, CEL36935), and the slides are ready to view under
microscope.

3.5 Frozen section and immunostaining (only for oval cell markers)
Liver samples were cut into 5 µm-thick pieces and immediately immersed into
CRYO-OCT Compound (Fisher Scientific, 14-373-65). After adjusting the tissue
position, the OCT cassettes were carefully held and put on top of isopentane, which
had been pre-chilled by putting into liquid nitrogen for at least 10 minutes. After about
2 minutes, when the OCT was frozen into a block, the block was either stored in -80°C
or directly sectioned. For the staining of the oval cell markers (Table 2), slides were
briefly fixed in cold acetone (-20°C) for 5 minutes. After washing off acetone with PBS
for three times and each time for 2 minutes, slides were added with 5% goat serum
and incubated for 10 minutes at room temperature to block non-specific antibody
affinity. Slides were then incubated with primary antibody for 30 min. After the primary
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antibody was washed off with PBS for 2 minutes in a total of three times, Cy3conjugated secondary antibody was added and the slides were incubated at room
temperature for 15 minutes. Again with PBS wash to get rid of excessive secondary
antibody, slides were sealed with anti-fade mounting solution with DAPI (invitrogen,
CEL36935), and signals were detected with confocal microscopy.
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Table 4. Antibody information

Antibody

Catalog

Applied

Dilution

number

experiment

ratio

IF

1:500

IHC

1:100

IF, IHC

1:1000

2922

WB

1:1000

552958

IF

1:200

Source

Dr. Valentina Factor
A6
(NIH)
BrdU

Abcam

ab6326

Dr. Milton Finegold
CK19

(Texas Children’s
Hospital)

Cyclin D1

Cell signaling
BD

F4/80
Biosciences
HNF4α

Santa Cruz

sc-101059 IF

1:200

Lats1

Cell signaling

9153

WB

1:1000

IF

1:20

Dr. Craig Dorrell
MIC1-1c3

(Oregon Health
Sciences Center)
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Mst1

Cell signaling

3682

WB

1:1000

Mst2

Cell signaling

3952

WB

1:1000

IF

1:20

Dr. Craig Dorrell
OC2-1D11

(Oregon Health
Sciences Center)

PCNA

Cell signaling

2586

WB

1:1000

Phospho-Lats1

Cell signaling

9159

WB

1:1000

Cell signaling

4113

WB

1:1000

Cell signaling

4911

WB

1:1000

P21

Cell signaling

2946

WB

1:1000

Sox9

Millipore

AB5535

IF

1:500

STAT-3

Cell signaling

9139

WB

1:1000

Yap

Cell signaling

4912

WB, IHC

1:1000, 1:500

Taz

BD Pharmingen

560235

WB

1:1000

PhosphoSTAT3
PhosphoYap/Taz

WB: Western Blot
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IHC: Immunohistochemistry
IF: Immunofluorescence
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3.6 PAS staining
Paraffin tissue sections were deparaffinized and rehydrated to water, followed by
being oxidized in 0.5% periodic acid solution for 5 minutes. After being rinsed with
distilled water for three times, slides were put into Schiff’s reagent (Sigma-Aldrich,
3952016) and incubated at room temperature for 15 minutes. The color (pink) was
developed under running warm tap water for at least 5 minutes. The slides were then
counterstained with Mayer’s hematoxylin for about 1 minute. After wash and
dehydration, the tissues were then sealed with Permount and ready to view under the
microscope.

3.7 Quantitative PCR
For each mouse, about one gram liver tissue was cut and put into 1 ml TRIZOL
reagent (Invitrogen, 15596-025), followed by being broken down using an electronic
homogenizer. Five hundred-microliter chloroform was then added to each sample tube
and mixed with TRIZOL well by vortex. The samples were then centrifuged at the
highest speed (14000g), and the supernatant was then transferred into Qiagen
RNeasy mini column for binding. After centrifuge, the mRNAs binding to the column
were washed by the RW buffer (Qiagen RNeasy Mini Kit, 74104), followed by washing
with 70% ethanol (prepared in DEPC-treated water). Finally, mRNAs were eluted with
into 15 ul RNase-free water. mRNA concentration and purity were checked with
NanoDrop 1000. Quantitative RT-PCR analysis was carried out using One-Step
TaqMan gene expression assays (Applied Biosystems) according to the
manufacturer’s instructions.
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Gene

Assay ID

lats1

Mm01191883

lats2

Mm01321139

yap

Mm00494237

taz

Mm00513560

gapdh

Mm99999915

3.8 Microarray analysis
Illumina Total Prep RNA Amplification Kit (Ambion) was used for preparation of
biotin-labeled cRNA samples. The microarray analysis was previously described [38].
Five hundred nanograms of total RNA was used for the cDNA synthesis, amplification
and biotin labeling. 1.5 µg of biotinylated cRNAs was hybridized to the Illumina mouse6 BeadChip v.2 microarray. Signaling reading is performed by the Microarray Core
Laboratory of UT Health Science Center in Houston. Heat-map of expression was
generated by Treeview. Gene ontology assay was performed using the DAVID web
tool.

3.9

Protein extraction
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Fresh harvested liver tissues were broken down into cells using a glass-teflon
homogenizer, or underwent perfusion to enrich hepatocytes. Then, cells were forced to
pass through a strainer to get rid of the connective tissue, and the hepatocytes were
collected into a 50 ml conical tube. The cells then underwent two times wash with PBS
and re-suspended in RIPA buffer (Cell signaling, #9806) added with protease inhibitor
(Roche, 04693132001) and phosphatase inhibitor (Roche, 04906837001). The cell
suspension was then put on ice for at least 30 minutes for sufficient lysate. Cell debris
was separated from lysate by centrifuging the tube at the maximum speed (14,000
rpm) for 5 minutes. The supernatant was transferred to a new clean tube, and about 2
ul aliquot was used for protein concentration measurement;
* Cytoplasmic and nuclear portion of proteins were extracted by NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Thermal Scientific, #78835) by following
manufacture’s protocol. Protein concentrations were measured by using BCA Protein
Assay Reagents (Thermal Scientific, 23227) according to the manufacture’s protocol.

3.10

Western blot:
Protein samples were denatured via boiling for 5 minutes with protein loading

buffer containing 5% beta-metheltransferase. Denatured samples were run on 10%
acrylamide denatured gels for 2 hours at 80 volts, followed by semi-dry transfer to
PVDF membranes (Millipore, IPFL10100) for 2 hours. The membrane containing
proteins was blocked from non-specific antibody binding with 5% milk in TBST for 1
hour at room temperature, and then incubated with primary antibody (Table 4) in 5%
BSA at 4℃ overnight. The next day, secondary antibody was added after the primary
49

antibody was washed off, and incubated with membrane at room temperature for 30
minutes. After further wash, membranes were developed by enhanced
chemiluminescence (ECL, PerkinElmer, NEL103001EA), and signal was detected by
X-ray film.

3.11 Hepatocytes enrichment (liver perfusion)
Prepare for the experiment by warming up HBSS (Invitrogen # 14170-11,
0.3mg/ml collagenase D), EBSS (Invitrogen #14155-063, 0.5mM EGTA) and Rinse
Medium (Invitrogen # 17704-024) to 37°C in water bath. Mice were then anesthetized
with IP injection of avertin (400-500ul/mouse). Mouse anesthetizing status was
checked by pinching the mouse toes for pain reflex. The mouse should not respond if
anesthetized. The mouse was body stretched by pinning the hand and feet to the
working platform. A U-shape incision was made to expose liver and inferior vena cava.
Buffer-fly needle was inserted into inferior vena cava. Right after the pump was turned
on, portal vein was cut to provide for exit of blood and perfusion liquid, and thus to
establish the perfusion reagents flow from the liver central vain to the portal vain. The
perfusion with EBSS lasted for 1-2 minutes (about 40 ml with pump set to 6-7, or 7-8
speed) and then switched to HBSS and perfused for 2-3 more minutes. When the liver
became soft, the pump was stopped and the liver was cut out. Gallbladder and fat
were removed by cutting off. Liver was then put in a 10cm petridish containing 20ml
RM and gently squeezed with two cell scrapers to release the hepatocytes from
connective tissue. The cells were then passed through a strainer into a 50ml Conical
tube. After the cells were rinsed with additional 10ml RM, they were spin at 600 rpm
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for 2 minutes and re-suspend in 10-25 ml RM. To remove the dead cells, Percoll
solution was prepared by mixing 15ml Percoll (Sigma #P4937) and 10ml DPBS in a
new 50ml conical tube, and cell suspension was slowly added into the percoll mixture.
The tube was centrifuged at 600rpm for 10 minutes, and dead cells were sucked off
from the upper layer. The remaining cell pellet was re-suspended and washed with
RM, followed by RNA isolation or protein extraction.

3.12 Partial hepatectomy
Five to 6 week old alb-cre;mst1/2 mice and 7-8 week old alb-cre;yap/taz mice
were used for performing 2/3 PH. The wild-type littermates were used as
corresponding controls. The mice were anesthetized with IP injection of avertin. After
briefly rinsing the feather with 70% ethonal, an excision was made in the middle of the
abdomen to expose the whole liver. Cotton tips were used to lift the left lobe and put a
15 cm silk suture under it. The suture was moved towards vena cava and a tie was
made close to it. The entire left lobe was removed with scissors. The middle lobe was
removed in a similar way but attentions were paid to not tie too close to vena cava.
Blood was briefly cleaned by using cotton tips, and the abdomen was closed up by
sewing the muscle and then the skin with silk suture. Morphine (5 mg/kg) was injected
to reduce pain, and then the mice were put on 37℃ incubator for recovery. Mice were
sacrificed at select time intervals: 0 hour (h), 6h, 24h, 48h, 72h, and 7days (7d) after
PH and the livers were harvested for protein extractions and paraffin sections. At 14
days, measurements were acquired for liver/body weight ratio. All the animal
procedures were performed in accordance with the MD Anderson Cancer Center
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institutional guidelines using an approved animal protocol by the Institutional Animal
Care and use committee.

3.13 Statistical Analysis
Student T-test was applied in MicroSoft Excel for two-sample comparison. Oneway ANOVA was used in SSPS program for three-sample comparison. Survival data
was analyzed using Kaplan Meier statistical method, and the survival curve was
generated in SSPS program.
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CHAPTER 4: RESULTS
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4.1 Mst and Sav1 are required for liver tumor suppression
Loxp-floxed alleles for mst1 and mst2, sav1 were successfully generated [38]. The
mst1/2 fl/fl and sav1 fl/fl mice showed no detectable abnormalities. Alb-cre;mst1 mice
and alb-cre;mst2 mice were also phenotypically normal up to 1 year of age. They
eventually developed liver tumors at around 24 months of age, implying they both are
required for liver homeostasis. However, a severe phenotype was observed when
combining Mst1 and Mst2 deletion: alb-cre;mst1/2 (double deletion) mice developed
multiple nodular tumors in the liver within 4 months after birth and died around 6-7
months (Figure 3C), implicating that significant functional redundancy exists between
Mst1 and Mst2 in suppressing liver tumorigenesis. The multiple gray-white nodular
tumors were identified as HCC (Figure 3F). Sav1-deleted livers showed a similar but
milder phenotype as compared with Mst1/2 double deleted livers. A few scattered
gray-white nodular tumors developed in the Sav1-deleted liver at about 8 months old.
The slower progression of liver tumors in Sav1 mutants allowed the mice to survive
longer and the tumors to fully develop (Figure 3B). Both HCC (Figure 3D) and
cholangiocarcinoma (Figure 3E) were observed in Sav1 mutants at around 18 months
of age. These observations revealed that both Mst and Sav1 are liver tumor
suppressors.
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Figure 3. Hepatoma formation in Mst and Sav1 mutants. Wild-type livers display a
normal appearance, devoid of tumor foci (A). In contrast, conditional deletion of sav1
in hepatocytes results in large, multifocal tumors (B). Likewise, alb-cre;mst1/2 mutant
livers are significantly enlarged relative to wild type and display multiple focal tumor
nodules (C). Histological examination (D-E) reveals both well and poorly differentiated
hepatocellular carcinoma (D and F) and cholangiocarcinoma (E). The data have been
published [38].
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To find out the cause of tumorigenesis in these mutants, mutants of younger ages
were collected and analyzed. In contrast to few sporadic hepatocyte divisions in the
wild type with normal low rate hepatocyte turnover (Figure 4A), the mutant hepatocyte
showed uncontrolled proliferation (Figure 4B and C) and mutant liver continuously
enlarged and eventually developed tumors (Figure 4D).

Figure 4. Elevated hepatocyte proliferation contributes to both Mst and Sav mutants’
liver enlargement. According to BrdU staining, in contrast to wild-type (A), albcre;mst1/2 (B) and alb-cre;sav1 mutants (B) have significantly increased hepatocyte
proliferation (C). (D) A plot of liver/body as a function of age shows increased liver size
of mst1/2 mutants at one month. Continued growth is evident at two and three months
of age. Modest increases in alb-cre;sav1 mutant liver sizes is seen at two and four
months of age. The data have been published [38].
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At 2-month old, there were no visible tumor-like nodules in the Mst mutants,
although the livers were dramatically enlarged (Figure 5B). Further HE Staining
revealed that the mutant hepatocytes gradually gained heteromorphism. At 1-month
old, there was no obvious difference between the wild-type and mutant hepatocytes; at
2-month old, the mutant hepaotocytes were swollen and their nuclei were smaller and
pushed to one side of the cells when compared with wild type (Figure 5D). The
swollen hepatocytes were not filled with excessive glycogen or fatty acids according to
PAS staining and Oil Red staining, respectively. So far, the cause of mutant
hepatocyte enlargement is still unknown, as is whether this contributes to liver tumor
development.
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Figure 5. Two-month old Mst1/2 double deleted liver. At this stage, the mutant liver is
dramatically enlarged but no visible tumor-like nodules are seen (B). Compared with
the wild type (C), the portal areas of the Mst1/2 double mutants have many leukocytes
expanding and infiltrating into the liver plates (D). The mutant hepatocytes are swollen
and their nuclei are more variable and pushed to one side of the cells [38].
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4.2 Yap is activated in alb-cre;mst1/2 and alb-cre;sav1 liver tumor tissues
Yap is a nuclear effecter of the Hippo pathway and its activation is known to
promote hepatocyte proliferation and contribute to HCC formation [34]. To see whether
Yap is activated in Mst and Sav1 mutants, western blots with proteins from enriched
hepatocytes before tumor formation were carried out. Results showed decreased
phospho-Lats and phospho-Yap in alb-cre;mst1/2 liver but not in alb-cre;sav1 liver
(Figure 6A). In both mutant tumor tissues, Yap was nuclear accumulated and the
protein amount was increased (Figure 6B), which was possibly due to protein
stabilization after decreased phosphorylation.
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Figure 6. Yap activation in Sav1 and Mst mutants. (A) Western analysis (by Wouter
Bossuyt) of alb-cre;sav1 and alb-cre;mst1/2 double mutant tissues show loss of sav1
protein in alb-cre;sav1 mutants and reduced amounts of mst1 and mst2 proteins in
alb-cre;mst1/2 mutants. Each lane represents proteins extracted from independent
mutant livers. Phosphorylations of Yap and Lats are reduced in alb-cre;mst1/2 double
mutant hepatocytes but not in alb-cre;sav1 mutant cells. Histone H3 (H3) is used as a
loading control. This datum has been published [38]. Yap staining in tumor tissues
reveals increased Yap protein amount, as well as Yap nuclear accumulation in tumor
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cells of both mutants (B).
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4.3 Lats is required for liver development
The loxp-floxed alleles of lats1 and lats2 were generated by Randy Johnson (not
published). Liver-specific deletions of Lats1 and Lats2 were achieved by combining
lats1fl/fl lats2 fl/fl homologs with alb-cre. The deletion efficiencies for both genes were
about 80% as assessed by quantitative PCR (Figure 7).

Figure 7 Quantitative analysis of Lats1 and lats2 gene deletion efficiency mediated by
alb-cre.
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Lats1/2 double mutants died from severe hypoglycemia on the first day of birth
(P0). According to PAS staining (Figure 8), two factors contributed to severe
hypoglycemia: hepatocyte loss due to hepatic necrosis and decreased glycogen
synthesis ability of hepatocytes. G/O assay with microarray data revealed essential
liver metabolic functional defects, including catalysis and biosynthesis (Figure 9C).
Furthermore, many up-regulated genes after Lats deletion were also up regulated in
Yap over-expressing liver (Figure 9B).

Figure 8. PAS staining on P0 Lats mutant livers. The result shows decreased glycogen
synthesis in Lats1/2 mutant hepatocytes as compared with that in the wild type. The
PAS staining is negative in the necrotic area (circled by the red dot line) and ductal
hyperplasia areas (circled by green dot lines).
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Figure 9. Global gene expression profiles of the Lats1/2 double mutants on P0. Heat
map (A) showed up (red) and down (green) regulated gene expression in Lats1/2
double deleted livers as compared to wt, among which the most upregulated genes
were selected and listed in B. The red highlighted genes are the ones that are also
upregulated in Yap over-expressed mutant livers. GO assay revealed the Lats1/2
deletion majorly affected liver metabolic function, together with alterations in
vasculature development.
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4.4 Biliary hyperplasia and liver stem cell activation in Mst, Sav1 and Lats mutants
A striking phenomenon in all three mutants (Mst, Sav1 and Lats) was the
expansion of BEC cells. In Sav1 mutants, BECs showed expansion at around 8
months (Figure 10C). In Mst mutants, BEC expansion started from 1 month old and
dramatically infiltrated into the liver plate at 2 months old (Figure 10B). Both mutant
livers had inflammatory response represented by increased macrophage population
(F4/80 positive, Figure 10E and F), suggesting there was chronic hepatic injury.
However, it is not known whether the BEC expansion is activated by hepatic injury
(cell non-autonomous) or intrinsic gene deletion (cell autonomous), or both. Similar but
more dramatic phenomenon was observed in Lats mutants at P0 (Figure 11 E and G),
suggesting bile duct developmental defects upon Lats deletion.
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Figure 10. Oval cell activation and inflammatory response in Mst and Sav1 mutants.
The A6 antibody, a marker for oval and ductal cells stains only ductal cells in wild-type
tissues (A), but stains both ductal cells and periductal cells in Mst1/2 mutants (B) and
Sav1 mutants (C). Inflammatory response is revealed by F4/80 staining, a marker for
macrophages. Both mutants show elevated macrophage population (E and F) [38].
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Figure 11. BEC hyperplasia in Lats1/2 mutants at P0. Lats1/2 double mutants die from
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hypoglycemia on P0. (A) In contrast to the even and smooth surface texture of the wild
type liver, Lats1/2 double deleted liver shows necrotic lesions (A). While BECs are
rarely visible in wild types by HE staining, many are found surrounding the portal area
in mutants (C). Consistently, both A6 and CK19 staining reveal expanded population
of oval/ductal cells in mutants (E and G).
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As liver stem/progenitor cells are believed to reside in the BECs and/or periportal
hepatocyte population [172,173], we used antibody staining to detect whether they
were activated together with BECs. Although there is no specific liver stem cell marker,
several antibodies (OC2-1D11, MIC-1c3, A6 and OC-6) that detect a heterogeneous
population of the immature hepatic cells have been generated [103,174,175,176,177]
and widely used for detecting immature hepatic cell population. We found liver
stem/progenitor cell activation in all three mutants (Mst, Sav1 and Lats) using at least
two of these antibodies (Figure 12, only one antibody staining is shown here for Sav1
due to poor image quality).
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Figure 12. Antibody characterization of liver oval cell. (A) The antibodies A6, OC21D11, and MIC1-1c3 stain ductal cells in wild-type (see WT 10X and 40X). At 2
months old, Mst1/2 mutants have increasing A6, OC2-1D11, and MIC1-1c3 positive
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cells surrounding the portal area and also infiltrating into liver plates. Sav1 mutants
also exhibit enhanced A6 labeling at four months of age. Antibody A6 and MIC1-1c3
recognize a few newly formed ductal cells in E18.5 wt liver. However, more positively
stained cells clustered and formed ductal structure in Lats1/2 mutants. All sections are
counterstained with DAPI.
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4.5 Yap and Taz are both dominant downstream inhibition targets of Lats
Although Lats is a broad governor for cellular homeostasis [53], Yap and Taz are
the only known proteins inhibited by Lats. In order to know whether Yap and Taz are
the main in vivo Lats interacting proteins that contribute to Lats mutant phenotypes, we
performed the rescue experiment by introducing floxed-allele Yap and Taz into the albcre;lats1/2 genetic background. The efficiency of alb-cre mediated Yap and Taz
deletions was accessed by both mRNA level and protein level (Figure 13A). Results
showed over 99% deletion of Yap (Figure 13B) and approximately 80% deletion of
Taz (Figure 13C).

Figure 13. Yap and Taz deletion efficiencies by alb-cre. (A) Western blot shows
reduced Taz protein level and almost undetectable Yap protein level in Yap/Taz
mutants, which are consistent with the mRNA level detected by real-time PCR, shown
in (B, Yap) and (C, Taz).
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Yap is required for bile duct formation and hepatocyte survival, but alb-cre;yap
mice are still viable and tumor free for more than one year [56], which potentiates the
outcome of longer lifespan of the alb-cre;lats1/2;yap mice if Yap activation does
contribute to Lats mutant phenotype. Our results support this speculation by showing
that the medium survival length of the alb-cre;lats1/2;yap mice was 12 days (Figure
14), which significantly extended Lats mutants lifespan (P0) by restoring glycogen
synthesis (Figure 15C). Deleting even one allele of the yap gene significantly rescued
the Lats mutant phenotype: ductal hyperplasia was reduced (Figure 16) and the
lifespan was extended with a medium survival length of 5 days (Figure 14). Thus, Yap
is a main Lats downstream inhibition target in vivo and its activation contributes
significantly to Lats mutant phenotype.
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Figure 14. Yap/Taz deletion rescues Lats1/2 mutants in a dose-dependant manner.
From the survival curve and the median survival length, Yap and Taz show dosage
effects in rescuing Lats1/2 double mutants neonatal lethality. While Yap appears to be
a major downstream effecter of Lats1/2 protein as its deletion extends Lats mutants
lifespan to a great degree, Taz is also indispensable for proper liver function, as Taz
deletion significantly increases Lats mutant and Lats plus Yap tri-deletion mutants’ life
spans.

74

Figure 15. Glycogen level comparison in the rescue experiment by PAS staining. (A)
Glycogen level in wild-type P0 liver. Lats1/2 double mutant have significantly reduced
the glycogen level (B). By combining Yap deletion, the liver actually shows an
increased glycogen level (C). The glycogen level is totally normal when combining Yap
and Taz deletions with Lats1/2 double deletion (D).
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Figure 16. Deletion of one allele of Yap decreases Lats1/2 double mutants’ ductal
hyperplasia. In P0 wild type liver, CK19 positive cells are few, surrounding the portal
vein. In alb-cre;lats1/2 liver, CK19 positive cells show hyperplasia. In albcre;lats1/2;yap/+ liver, the number of CK19 positive cells is between these of the wildtype and alb-cre;lats1/2; Ductal structural can be seen, although slight hyperplasia still
exists.
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Taz is a paralog of Yap and also biochemically phosphorylated and inhibited by
Lats. So far, there has not been any report about Taz function in the liver. In
characterizing of alb-cre;yap;taz liver, we found that further Taz deletion did not
significantly elevate the mutant phenotype of the Yap deletion. Similar phenotypes
showing increased hepatocyte turnover (Figure 17) and defects in bile duct
development were found (Figure 18). The alb-cre;yap;taz mice were viable and tumor
free up to 1 year old. As with Yap, to test whether Taz is a down-stream target of Lats
and contributes to Lats mutant phenotype, Taz deletion was introduced into a Lats
mutant genetic background. The significantly extended median survival time (5 days)
of the alb-cre;lats1/2;taz mutants (Figure 14) revealed that Taz is also a main Lats
downstream inhibition target and its activation contributes to Lats mutant phenotype.
Moreover, according to the survival curve (Figure 14), the mutants’ median
survival time was extended as one more allele of Taz and Yap were deleted,
suggesting that Taz and Yap rescued Lats mutant lethal phenotype in a dosagedependent manner on the basis of a single allele. Furthermore, synergistic effect
between Yap and Taz may exist as Yap and Taz double deletion showed the most
dramatic rescue effeciency, which was significantly different from those of either Yap
or Taz deletion.
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Figure 17. Increased hepatocyte turnover in Yap/Taz double deleted liver. The mutant
liver is larger (B) as compared to wild type (A). The mutants’ mean liver/body weight
ratio is slightly higher than wild type (C), which is due to continuous hepatic
proliferation (E and F). In addition, the mutant liver shows increased inflammation and
engulfment of hepatocytes by macrophages (H). Mutant hepatocyte injury is
represented by increased AST and ALT level (I).
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Figure 18. Bile duct malformation in Yap/Taz double deleted liver. Mice with liverspecific deletion of Yap/Taz are viable, however the liver has a larger gallbladder and
develops adenomas at around one year of age (B). Adenoma is a kind of benign tumor
that characterized by loss of bile ducts. Though in mutants some areas still develop
bile ducts, they are malformed as shown in HE staining (D) and CK19 staining (G,
arrowed). C and F show the morphology of normal bile ducts in wild type.
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4.6. Yap increase/activation correlates with BEC expansion in Lats mutant.
Interesting questions have arisen regarding the cause of biliary hyperplasia in
Mst, Sav1 and Lats mutants and whether it is cell autonomous or non-autonomous. As
Mst (facilitated by Sav1) inhibits Yap/Taz through Lats, it is very likely that the
activated Yap activity is responsible for the biliary hyperplasia in all three mutants. We
further investigated the mechanism of biliary hyperplasia in the Lats mutant. Due to the
fact that Lats functions downstream of Mst, and also because Lats mutants show the
most dramatic biliary hyperplasia, their use will facilitate the detection of abnormalities.
The intrahepatic bile duct (IHBD) plates form around E14.5 [178,179]. Therefore,
mutant and wild type livers from E15.5 to E18.5 were collected to investigate the
progress of biliary hyperplasia. Double staining of CK19 and Ki67 revealed that
elevated BEC proliferation started from E16.5 and became dramatic at E17.5 (Figure
19). Interestingly, Yap was dominantly expressed in BEC-like cells and increased Yappositive periportal cell population also starting from E16.5 and further elevated
afterwards (Figure 20). The correlation between these two observations supports our
speculation that activated Yap is responsible for biliary hyperplasia. Thus, cell
autonomous proliferation contributes, at least partially, to the biliary hyperplasia in all
three mutants. Furthermore, Yap may be a new BEC marker, whose level/activity
regulates bile duct development. Double staining of Yap with a known BEC marker
(e.g. CK19 and Sox9) is required to confirm this theory.
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Figure 19. BEC proliferation in Lats mutants starting from E17.5. (By Kilang Yanger,
University of Pennsylvania)
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Figure 20. Yap positive cells expand in Lats mutant. Yap antibody positively stains bile
ductal-like cells in wild-type livers (A, C and E). Yap positive cells in Lats1/2 double
mutants are dysplasic and show progressive hyperplasia, and their nuclei are
pleomorphic (B, D and F).
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4.7 Notch signaling is activated in Lats mutant periportal area
We further investigated whether the dysregulation of the Hippo pathway has
impact on classic signaling pathways that are essential for bile duct development. As
Jagged1 gene expression is significantly increased in both Lats deleted liver (Figure
9) and Yap overexpression liver [34], Notch signaling becomes a promising target
candidate for our investigation. By double staining of Jagged1 and CK19, a close
association between Jagged1 positive cells and expanding CK19 positive cells was
revealed. Moreover, known Notch signaling downstream gene targets (Hes1 and Ostp)
were activated surrounding the portal area with biliary hyperplasia (Figure 21). These
results revealed that Notch signaling was elevated upon Lats deletion in the portal
region, and thus contributed to biliary hyperplasia by enhancing BEC-fate
determination and promoting bile duct tubular morphogenesis.
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Figure 21. Notch signaling activation in the periportal area of E18.5 Lats mutants. (By
Kilang Yanger, University of Pennsylvania)
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4.8 Yap and Taz are activated during liver regeneration
Because Yap and Taz are nuclear effectors of the Hippo pathway, their activities
can manifest Hippo pathway activity. Yap and Taz phosphorylation and protein levels
were analyzed during liver regeneration as indicators of potential correlation between
Hippo pathway activity and liver re-growth.
To cover all three liver regeneration phases, six time points were chosen for
protein analysis: 0h (hour), 6h, 24h, 48h, 72h and 7 days. Western blot analysis
showed a correlation between Taz activity and regeneration progress: nuclear
unphosphorylated Taz increased in the priming and proliferative phases (evidenced by
decreased cytoplasmic phospho-Taz and increased total Taz, Figure 22A), and
decreased in the termination phase (evidenced by increased cytoplasmic phospho-Taz
and decreased total Taz). However, phospho-Yap and total Yap changed in the same
direction, therefore we were unable to determine the coupling between nuclear
unphosphorylated Yap and liver regeneration based on total protein analysis (Figure
22B). For this reason, we further used nuclei-cytoplasm protein extracts to detect the
active form of Yap (unphosphorylated) in the nuclei. Results showed a slight increase
of nuclear Yap levels during the proliferative phase (Figure 22C), suggesting that Yap
was also activated. To exclude any artificial results from the surgery procedure,
pseudo-surgery (sham) were carried out and mice were sacrificed at exactly the same
time points with that of the PHx mice. Phospho-Yap, P21 and PCNA protein levels
were checked, and the results showed no change along all the time points that tested,
implying the surgical procedure does not affect the proteins’ activities or levels (Figure
22D).
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Figure 22. Yap and Taz activities during normal liver regeneration. During
regeneration, Taz phosphorylation is decreased while its total protein level is
increased (A). Yap phosphorylation is decreased at 6h after PH, however increases
afterwards. The total Yap amount shows a similar trend during regeneration (B).
Further nuclear and cytoplasmic localization examination show increased Yap nuclei
localization along regeneration (C). Yap phosphorylation, PCNA, and P21 expressions
are not altered in pseudo-surgery (sham) group (D).
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4.9 Yap/Taz null and Mst1/2 null livers show impaired regeneration
In order to further investigate whether Yap/Taz is required and sufficient to
promote liver regeneration, Yap/Taz deletion (alb-cre;yap/taz) and Yap/Taz activation
(alb-cre;mst1/2) mice were subjected to PH. To reduce the original liver size variation
of the Mst1/2 mutant, PH was performed in young mice (5- to 6-week old). According
to our previous report, Mst1/2 mutant liver size variation at 1 month is much less than
at 2 months [38].
Re-growth percentage and hepatocyte proliferation were accessed as parameters
for liver regeneration ability. While wild-type livers could fully (100%) re-grow back to
their original sizes, both Yap/Taz and Mst1/2 mutants re-grew to approximately 70% of
their original sizes (Figure 23A). Decreased hepatocyte proliferation was likely the
main reason according to BrdU incorporation assay (Figure 23B). As Yap and Taz are
the main effecters of Hippo signaling and their pro-proliferation functions are the
theoretical basis for the hypothesis that Hippo pathway regulates organ size, the 70%
regeneration ability of the Yap/Taz null liver suggests that the Hippo pathway is not
critically required for liver regeneration. The impaired regeneration is possibly due to
the disease effect from early embryonic deletion of Yap/Taz. For the same reason, it
remains unknown whether activated Yap/Taz (Mst null) can promote the liver to a
larger setting point. It should be tested in a way that allows avoidance of the disease
effect of Mst by deleting the genes prior to PH surgery, possibly, by introducing crerecombinase adenovirus through tail-vein injection. From the fact that the liver can still
regenerate without Yap and Taz, it can be concluded that Hippo signaling is not a sole
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determinant for liver regeneration, or for liver size setting point. Another interactive
network must compensate the Hippo pathway’s role in liver regeneration.
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Figure 23. Both Mst1/2 double mutants and Yap/Taz double mutants can regenerate
to approximately 70% of their original sizes. (A). Neither mutants’ hepatocytes can fully
proliferate responding to regeneration signals. Mst1/2 mutants have significantly
retarded hepatocytes proliferation at the peaking time point (2 days after PH). The
represented BrdU staining of samples of day-2 after PH shows decreased Yap/Taz
mutant hepatocyte proliferation (D), as well as decreased Mst1/2 mutant hepatocyte
proliferation (E), as compared to normal hepatocyte proliferation(C).
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4.10 Hippo signaling regulates the timing of hepatocyte proliferation
Liver regeneration is indeed a process of synchronized hepatocyte cell-cycle
progression [166,180]. Although many genes’ loss-of-function do not completely inhibit
liver regeneration, they often affect the timing of hepatocyte cell-cycle progression
[131,164,181,182]. We therefore also investigated the timing of the Yap/Taz-null and
Mst-null hepatocyte cell-cycle progression, specifically, the timing of the cell-cycle
reentry.
A critical step of cell cycle progression is cell cycle initiation, in which cells pass
through the G1 phase cell cycle checkpoint and enter the DNA-synthesizing S phase.
Yap/Taz double mutants had higher Cyclin D1, P21 and PCNA baseline levels before
PH (0h), which were likely due to cell non-autonomous compensatory growth. After
PH, however, a synchronized but delayed expression pattern was seen (Figure 24A).
Specifically, Cyclin D1 expression peaked at 72 h after PH in mutants, which was 2
days later than the wild-type littermates. The timing of STAT3 signaling (known to be a
master regulator for the timing of hepatocyte cell-cycle reentry [183]) was unchanged
although enhanced at the 24h time point (Figure 25A), suggesting the Yap/Taz
deletion may affect the downstream of STAT3 signaling and caused the delay of
CyclinD1 expression.
The same analysis was performed in Mst1/2 double mutants. Instead of delayed
cell cycle re-entry, Mst null hepatocytes showed a persistent proliferation pattern
(Figure 24B). Similar to Yap/Taz null hepatocytes, the timing of the STAT3 activity in
Mst null hepatocytes was unchanged, but slightly elevated at the 24h time point
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(Figure 25B), suggesting that the Mst deletion also caused effects downstream of
STAT3 signaling and disrupted the synchronization of cell cycle re-entry.
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Figure 24. Cell cycle progression is delayed during Yap/Taz double mutants’
regeneration. (A), and advanced during Mst1/2 double mutants’ regeneration (B).
Yap/Taz double mutants (A) have higher Cyclin D1, PCNA and P21 basal level before
regeneration (0h). Responding to the regeneration signal, Cyclin D1 in mutants shows
maximal expression at 72 h, which is 2 days later than the wild-type littermates’ (24h).
Peaking expression of PCNA in mutants is still at 48h, but the level is lower than that
of wild type. Peaking expression of P21 in Yap/Taz mutants is at 72h, which is oneday delayed as compared to the wild-type littermates. In Mst1/2 double mutants (B),
the basal levels of PCNA and Cyclin D1 are higher, however, P21 was lower as
compared with wild-type littermates’. Cyclin D1 peak level is at 24h in Mst1/2 mutants,
but occurs at 48h in the wild type littermates. PCNA level increases immediately after
PH and remains persistently high afterwards, even at 7d after PH. P21’s peak time in
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mutants is the same as in the wild-type littermate’s (48h after PH); however, the
protein level is higher as compared to wild-type littermates. Actin is used to show
relatively equal loading among samples.
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Figure 25. STAT3 activity during regeneration. In wild type liver regeneration, STAT3
peaks at 24 h after PH. In both Yap/Taz and Mst1/2 double mutants, STAT3 still peaks
at 24h time point, but the levels are higher than at the same time point in wild types.
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CHAPTER 5: DISCUSSION
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Our study is among the first ones that address the Hippo pathway function in a
mammalian system. We have shown that although the Hippo pathway functions
ubiquitously in regulating tissue homeostasis, it has certain tissue specificity in the
liver. Our work has addressed how the main components function individually in the
live. Results show that the Hippo pathway is not only involved in maintaining liver
homeostasis, but is also required for the liver development. Furthermore, we found
evidence that the Hippo pathway interacts with Notch signaling in regulating the biliary
system. However, in terms of the organ size control function, it is not the sole
determinant of the organ size setting point, but does influence the timing of hepatocyte
cell cycle progression. As tumor development is often associated with disturbances of
the cell cycle regulation, the Hippo pathway may suppress liver tumor development
through surveilling the hepatocyte cell cycle progression. Our study is significant in
advancing understanding of the tumor suppression mechanism and in helping to
develop potential therapeutic approaches for liver cancer.
5.1 Mst in liver tumor suppression
Before Mst was recognized as the “Hpo” kinase in the Hippo pathway, it was
known for its role in mediating the apoptosis induced by cellular stress
[184,185,186,187]. Except for its ability to form complexes with members of the Rassf
family [52,188], which are known to be tumor suppressors, no direct evidence
supported Mst being a tumor suppressor. When its Drosophila ortholog, the Hpo
kinase, was characterized, new insights into the role of the Hippo pathway as a
suppressor of tissue growth were gained. Mst was hypothesized to be a tumor
suppressor in the mammals. To test this hypothesis, several groups, including our lab,
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generated Mst1 and Mst2 conditional knockout mice and analyzed their phenotypes
[37,38,41]. While the other groups studied Mst function only in the liver as inspired by
the first report about Yap over-expression in liver resulting in HCC ([34]), we tested
Mst function in several tissues by using both tissue specific (villin-cre) and widelyactive cre (MMTV-cre, and Caggs-cre) lines. We found that Mst most likely has a
ubiquitous function in tissue homeostasis, but also has certain tissue specific functions
in the liver. The underlying mechanism is yet not known.
Different research groups consistently reported that HCC developed as a
consequence of Mst deletion, suggesting that the Mst is an important liver tumor
suppressor. Before tumor development, Mst null livers were bigger than normal due to
increased hepatocyte proliferation and suppressed apoptosis [38,41,189], a feature
reminiscent of the Hpo mutant phenotype in Drosophila. Yap activation was also
consistently observed in the Mst null liver, which supported our hypothesis that the
mammalian Hippo pathway is a tumor suppressor pathway. However, several
inconsistencies exist between the Mst null livers generated by different labs. First of
all, there is controversy of whether Lats mediates Yap inhibition by Mst: we found that
the Lats phosphorylation was depleted in the Mst null hepatocytes [38]; another group
claimed that Lats phosphorylation was unaffected upon Mst deletion [189]. The reason
for this disagreement may be due to different cell types used in each experiment. We
used the enriched hepatocytes, and the other group used Mst null MEFs. Whether Mst
inhibits Yap through different mediators in different tissue contexts or cell types may
be addressed by testing in other tissue types or in different cell lines.
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Another disparity is in the histology results of Mst-null livers generated by different
labs. Dr. Yingzi Yang’s group and our group observed systematically inflammatory
response in the Mst deleted liver resulting in infiltration of the macrophages together
with liver progenitor cells into the periportal area [38,41]. This phenotype was not
obvious in the Mst-null liver mouse model generated by Dr. Nabeel Bardeesy’s lab
[189]. In addition, mutant liver with systematic inflammatory response developed
tumors in multifoci or a diffuse fashion [38,41], while the one without obvious
inflammatory response developed tumor in unifoci [189]. By looking into the way these
mutants were generated, we believe that the genetic differences contribute to these
phenotypic inconsistencies. Dr. Yingzi Yang’s group and our group used alb-cre to
deletion both Mst1 and Mst2 at the same time (alb-cre;mst1/2fl/fl), while Dr. Nabeel
Bardeesy’s group deleted Mst1 in the germline and later deleted Mst2 in liver by albcre (alb-cre;mst1∆/∆;mst2∆/fl). Mst1 is an important regulator of T-cell maturation,
adhesion and migration [190,191]. Under pathological conditions, such as bacterial
and viral infection, liver immune cells including küpffer cells, NK cells, NKT cells, and
T-cells are activated in a positive feedback loop to protect the host from bacterial and
viral infections [192]. As the fetal liver is a major site of development of the immune
system [193], germline deletion of the Mst1 may impair the development of T-cells,
disrupt the immune response loop and disable the inflammatory response that would
occur when Mst2 is further deleted by alb-cre. Persistent inflammation is the main
cause of liver cirrhosis and subsequent development of HCC (reviewed in [194,195]).
The systematic inflammatory response in the alb-cre; mst1/2fl/fl mice is very likely the
main reason for the early development of multifocal cancerous lesions, which
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accelerates the liver disease progression from the genetic alteration (i.e. Mst deletion).
As a consequence, alb-cre;mst1/2fl/fl mice have a shorter lifespan (6-7 months) [38,41]
compared with the alb-cre;mst1∆/∆;mst2∆/fl mice (12-15 months) [189].
While the detailed mechanism of inflammatory response and tumor initiation in
Mst-null liver is still not clear, there are several possibilities may apply. One is
epigenetic alteration caused by Mst gene deletion. There are accumulating evidence
that epigenetic mechanisms are essential for both normal development and cellular
homeostasis. Global changes in the epigenetic landscape are a hallmark of cancer
[196]. Mst can indirectly affect gene expression through inhibiting Yap, but also can
directly regulate gene expression through interacting with chromatin. Over-expression
of Mst can induce chromatin condensation through phosphorylation of histon H2B and
H2AX [197,198] [199] and may thus regulate gene expression at the epigenetic level.
Another possibility is the accumulation of DNA damage during mutant hepatocyte
proliferation. One of Mst phosphorylation targets, the γH2AX, plays an important role in
DNA double-strand break (DSB) repair [200,201,202] and has become a biomarker for
measuring DNA damage [203]. Deletion of Mst may impair the DNA-repair mechanism
through inhibiting γH2AX, resulting in DNA damage accumulation. DNA damage
contributes to cell necrosis and release of dead cell cytosol, which triggers the
inflammatory reaction and promotes tumorigenesis. A good example is the HCC
induction by the carcinogen diethylnitrosamine (DEN) [204,205].
In conclusion, Mst is a liver tumor suppressor. It suppresses liver tumor formation
by maintaining hepatocyte quiescence and liver homeostasis. It may provide a good
model for studying inflammatory response and testing the corresponding treatments.
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5.2 Lats in liver development
Lats is believed to be a broad governor of cellular homeostasis because of its
involvement in many important cellular processes, including proliferation, apoptosis,
senescence, transformation, and migration (reviewed in [53]). At the molecular level,
multiple domains enable diverse functions such as protein-protein interaction and
phosphorylation. Therefore, although Yap and Taz are so far the only known
substrates of Lats, multiple substrates are predicted and there is ongoing research that
aims to identify other Lats substrates by using consensus phosphorylation sequence
of Lats. However, our in vivo genetic analysis about the relationship between Yap/Taz
and Lats revealed that Yap and Taz are the main substrates of Lats (Figure 14). This
close relationship between Yap/Taz and Lats may have liver-tissue specificity since
Lats specific transcriptional targets identified in Hela cells suggest that the Lats
functions through multiple pathways [53,206].
Although Lats contributes to many cellular events, how it functions in vivo and
contributes to organ function is not known. Our work is the first one to study the Lats
function in vivo by double deletion of the two Lats paralogs (Lats1 and Lats2). We
found that Lats may participate in governing the cholangiocyte-lineage formation
through restricting both Yap activity and Yap protein levels. Through microarray
analysis and immunostaining, we found that upon Lats deletion, the Notch signaling
required for biliary differentiation and morphogenesis [81,82,83,87,88] was activated
(Figure 21) while Tbx3, which globally inhibits the biliary differentiation [207], was
suppressed. These changes may thus switch a normal liver developmental
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environment to the one that favors the biliary development. Although hepatocytes still
developed, microarray data on postnatal day 0 liver showed a global decrease in all
most all the hepatocyte functions (Figure 9). This may be a result of immature
hepatocyte development due to Lats deletion.
The mechanism of Lats control of hepatic lineage differentiation is yet unknown.
One of the possible mechanisms is through interaction with the Notch signaling
pathway. Elevation of Jagged1 gene expression in both Lats-deletion mutants and
Yap-over-expression mutants suggests that Jagged1 may be a direct gene target of
Yap. If so, Lats-Yap(/Taz) may affect the bile duct development by regulating the
Jagged1 expression and its downstream Notching signaling. In addition, Sox9 is also
up regulated in both Lats deficient mutants and Yap-over-expression mutants, which
suggests that Sox9 could be a direct target gene of Yap. Sox9 is a BEC marker
regulated by Notch signaling during biliary morphogenesis [77,82]. These results point
towards a certain interactive relationship between the Hippo pathway and the Notch
signaling. Diagram 5 shows the possible relationship between the two pathways
based on the assumption that jagged1 and sox9 are direct gene targets of Yap. How
the two pathways together regulate bile duct development is particularly interesting
because it may help advance understanding of the mechanism of human Alaggille
syndrome (AGS). AGS is a genetic disorder characterized by abnormalities in liver,
heart, eye, skeletal, craniofacial and kidney [208]. It is caused by a null mutation in
Jagged1. In liver, Jagged1 deletion results in bile duct paucity and chronic cholestasis
[84,86], which is one of the life-threatening symptoms in AGS patients. Obviously,
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Jagged1 plays an important role in bile duct development, and understanding its
regulation will be of course important for developing the treatments for AGS patients.
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Diagram 5. Potential Hippo pathway function in bile duct development. The Hippo
pathway inhibits Yap/Taz through phosphorylation. Unphosphorylated Yap (and likely
Taz too) is likely to associate with some unknown transcription factor, and activating
jagged1 and sox9 transcription, which contributes to the activation of Notch signaling
and subsequent bile duct development. The relationships marked by dashed arrow
lines need to be experimentally confirmed.
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A major conclusion from the above discussion of the phenotypes of Mst and Lats
mutants is that, Mst is important for the liver homeostasis because of its ability in
reducing the inflammatory response; while Lats more closely interacts with Yap and
regulates cellular behavior through controlling the hepatic transcription profile.
Although the Mst-Lats-Yap linear kinase cascade is still present, the function of the
mammalian Hippo pathway is complicated by the diverse individual functions of its
components. Moreover, existence of multiple versions of Hippo pathway proteins may
complicate the pathway further by adding other regulatory inputs. There is emerging
evidence that Mst3/4 interacts with Ndr1/2 (Lats family proteins) in regulating Yap
activity [209,210]. Despite the complexity of the pathway’s upstream regulation, Yap
and Taz are so far the only known nuclear effecters of Hippo signaling. The significant
rescue effect of Yap/Taz deletion on Lats mutants (Figure 14) and Mst mutants (by
other lab members) clearly suggested that Yap/Taz is the key element of the Hippo
pathway in regulating liver homeostasis. As Yap activation is highly associate with the
poorly differentiated HCC and a low patient survival rate [51], Yap may be a promising
therapeutic target for HCC treatment.
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5.3 The Hippo pathway in liver size control
How organ size is controlled is a fundamental biological question. The prevailing
opinion is that organ size is regulated by an intrinsic “total mass checkpoint”
mechanism (reviewed in [211]). This mechanism ensures that organs maintain an
inherited size through modulating the number and the size of their constituting cells.
Classic Drosophila genetic screening for genes involved in this mechanism has
identified the Insulin-PI3K-Akt signaling pathway and dTOR (Drosophila target of
rapamycin) pathway as playing central roles. The two pathways merge at S6K, which
regulates a cell’s overall mRNA transcription and thus affects cell growth/size
(reviewed in [211,212,213]). In contrast, the Hippo pathway appears to mainly affect
cell proliferation and survival, and thus regulates organ size via the number of cells.
Liver is known for its unique ability of regeneration, by which it is able to keep a
constant size through a checkpoint, or setting point. The regeneration process is
strictly controlled by signaling networks with functionally redundant intracellular
components, and thus loss of an individual gene rarely leads to complete inhibition of
liver regeneration. Therefore it is not surprising to see that Yap/Taz null liver still can
regenerate to about 70%. Actually, there is speculation that Yap/Taz null liver may be
able to regenerate 100% of its original size if Yap/Taz is deleted right before surgery,
which prevents the disease effect from embryonic gene deletion. The impaired
regeneration in both Yap/Taz-null and Mst-null livers may be a result of this disease
effect. To avoid the disease effect, recombinant adenovirus-cre recombinase can be
introduced into liver through tail-vain injection right before surgery. However this
technique modification will not change our current conclusion that the Hippo signaling
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is not a critical determinant for liver size control, because the deletion of Yap/Taz does
not dramatically inhibit liver re-growth.
Although individual component deletion rarely inhibits liver regeneration, it often
impairs hepatocyte proliferation [183,214] or delays the timing of regeneration phases
[181,182,215,216]. In our study, Mst null liver had a disrupted synchronization of
hepatocyte cell cycle progression, while Yap/Taz null liver showed a delayed
hepatocyte cell cycle re-entry. Because Mst-null liver and Yap/Taz-null liver are
supposed to have opposite effects on Yap/Taz activity, and Yap/Taz is known to
promote cell proliferation, the difference between the two cell-cycle progression
patterns suggests a dominant role of Yap/Taz in promoting cell cycle re-entry, i.e. the
G1/S transition. It is likely that the activated Yap/Taz (in Mst-null liver) overrides the
normal regenerative rhythm and activates the G1/S transition regardless of the normal
timing; whereas in the absence of Yap/Taz (Yap/Taz-null liver), the intrinsic
regenerative mechanism may lack the proliferative inducing signal at the beginning,
but this lacking can be eventually compensated for by other signals and therefore the
regeneration rhythm appears to be delayed. The point here is that although Yap/Taz
regulates cell cycle re-entry, there are compensatory mechanisms during liver
regeneration that substitute when the Yap/Taz function is not available. Our finding
complies with the general thinking that liver regeneration is well controlled by signaling
networks with functionally redundant components, and loss of an individual component
rarely leads to complete inhibition of liver regeneration.
Emerging evidence suggests that the Hippo pathway may interact with the mTOR
pathway and the PI3K/Akt pathway, both of which are known to be important for liver
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regeneration. Evidences for the interaction between the Hippo and mTOR pathways
includes: 1) deletion of Mer/NF2 results in activation of mTORC1 [217,218], which is
an mTOR kinase inhibitor complex; 2) loss of Mst activates mTORC1 [189] and affects
mTORC2 downstream signaling [219]; and 3) Yap regulates IGF-1, which is a known
activator of the mTOR pathway [220]. Furthermore, the transcription factor Myc has
been identified as a gene target of Yki [221,222], and it has also been shown to affect
the transcription of TSC2 by binding to its promoter [223]. It has been reported that
activation of the TOR pathway leads to increased cell growth and cell cycle re-entry
[224,225,226]. In a liver subjected to partial hepatectomy, mTOR pathway appears to
regulate liver regeneration by modulating cell growth and proliferation in response to
the energy demands of the remaining liver [227,228,229]. The interaction between the
Hippo and PI3K/Akt pathways is more direct: Akt directly phosphorylates Yap to
induce interaction with 14-3-3 and result in functional inhibition [230]. Akt also
indirectly activates mTOR pathway by regulating cellular ATP levels and AMPK activity
[231,232]. The three pathways form a network and may compensate for each other in
regulating liver regeneration and liver size. In the Yap/Taz null liver, PI3K/Akt may
elevate mTOR pathway activity in response to insufficient cell proliferation, resulting in
liver mass re-growth with a delayed timing of cell cycle progression. The diagram
below illustrates the possible regulatory mechanism of liver regeneration by the three
pathways (Diagram 6).
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Diagram 6. Both Akt and Mst can inhibit either mTORC or Yap/Taz. mTORC inhibits
mTOR kinase, which otherwise promote cell growth and cell proliferation. Akt and Mst
control both mTOR activity and Yap/Taz activity, and may thus modulate the two
pathways to achieve liver size control.

108

CHAPTER 5: FUTURE STUDIES
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In mouse, Yap over-expression drives liver tumor development [34]. In human
liver cancer patients, Yap hyper-activation is correlated with tumor malignancy and low
patient survival rate [51]. Study Yap function in liver is therefore important for
understanding liver cancer initiation, and may help to develop strategies for liver
cancer diagnosis and treatments.
Yap is a transcription cofactor that regulates target gene expression by binding to
transcription factors. Domain analysis revealed that Yap has the potential of binding to
a variety of transcription factors via its WW-domain [57,233]. Several Yap-interacting
transcription factors have been reported [65,66,230]. However, their interactions with
Yap have not been tested in vivo, nor do they give a systematic view about Yap
function in liver. Microarray data of the Lats deficient liver and the Yap over-expression
liver provide an overview on the gene population affected by Yap, but the ones directly
regulated by Yap and contributing to liver homeostasis are not known. To address the
above questions, it is important to find out the transcription factors that Yap directly
associated with in liver.
Functional protein arrays are emerging as a new tool for studying protein-protein
interaction in a large scale (reviewed in [234]) and can be used to identify the Yapbinding transcription factors. Potential candidates should be verified by IP (immunoprecipitation) assay and their functional contribution to Yap can be tested in cell culture
system or mouse. Below shows an example of studying the interaction between Yap
and one of its potential interacting transcription factors in regulating bile duct
development.
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In our study, Yap up-regulation correlates with biliary hyperplasia and decreased
hepatocyte function, suggesting a possible mechanism that Yap activates a gene
profile in favor of BEC differentiation and bile duct development. If this is true, then the
Yap function is opposite to the transcription factor C/EBP (CCAAT/enhancer-binding
protein), specifically, C/EBPα, which plays an important role in promoting hepatocyte
differentiation and inhibiting biliary cell differentiation [235,236,237,238]. Analysis of
the protein domains of C/EBPα and Yap predicts a possible physical interaction
between the two. This suggests a role for Yap in promoting bile duct development
through inhibiting C/EBPα (Diagram 7).
C/EBP is a leucine zipper transcription factor widely expressed but primarily in
tissues known to metabolize lipid and cholesterol-related compounds at uncommonly
high rates, such as liver, fat and intestine [239]. Six isoforms of the C/EBP have been
isolated (C/EBPα to ς), among which the C/EBPα is the first one cloned [239,240] and
has been extensively studied. C/EBPα is detected only in differentiated tissues
[239,241], and therefore being implicated in regulating the terminal differentiation of
mammalian cells, including hepatocytes. C/EBPα is expressed at high levels in
hepatocytes, where it regulates a variety of hepatocyte-specific genes, such as serum
albumin [242], haptoglobin [243], phosphoenolpyruvate carboxykinase (GTP) (PEPCK)
[244], etc. Its importance for hepatocyte function is also reflected by its inhibitory effect
on biliary cell differentiation [236,237]. Suppression of C/EBPα expression increases
Hnf6 and Hnf1b, two important transcription factors in biliary cell differentiation,
[245,246]. Over-expression of C/EBPα can even cause trans-differentiation of
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pancreatic cells to hepatocytes [247], demonstrating its essential role in hepatocyte
fate determination.

Diagram 7 Hypothesized Yap function in biliary cell differentiation. (A) With low level
or no Yap expression, C/EBPα activates genes essential for hepatocyte differentiation
while suppressing BEC essential genes. (B) In the presence of Yap, C/EBPα
transcriptional activity is suppressed, leading to a switch of the downstream gene
expression pattern from hepatocyte differentiation to BEC differentiation.
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We hypothesized that Yap promotes bile duct development through inhibiting
C/EBPα (Diagram 7). To test this hypothesis, three questions can be investigated.
First, does Yap over-expression suppress the C/EBPα activating genes, such as
albumin, hepatoglobin, and urea cycle enzymes, and at the same time induce Hnf6
and Hnf1b expression (Diagram 7)? Second, does Yap deletion block biliary cell
differentiation? Third, would a C/EBPα dominant mutation antagonize the biliary
differentiation promoted by Yap over-expression?
To reduce cell non-autonomous effects, assays and tests can be carried out in a
primary hepatoblast culture system. Hepatocyte differentiation can be induced by
Oncostatin M (OSM) [248,249,250] and the effect of Yap and C/EBPα interaction on
regulating hepatic differentiation can be accessed by detecting the expressions of both
hepatocyte and biliary cell-specific genes (Diagram 6). To test the direct inhibition
effect of Yap on C/EBPα, mutations can be introduced into the PPXY motif (where it
binds to Yap) of C/EBPα through gene targeting. This mutated form of C/EBPα should
be unaffected by Yap and therefore promoting hepatocyte differentiation regardless of
Yap activity. The hypothesized Yap- C/EBPα interaction in regulating hepatoblast
differentiation can be further tested in vivo through transplantation into the testes of
SCID (severe combined immune deficient) male mice. The testes of SCID male mice
provide an ideal in vivo environment for cell survival and growth. When liver fragments
are transplanted into the testes of SCID mice, normal hepatoblasts can construct
mature hepatic tissue accompanied by biliary cell differentiation, whereas the C/EBPα
deficient hepatoblasts only give rise to biliary cells [237]. If Yap do regulate biliary cell
differentiation through inhibiting C/EBPα, then Yap over-expression will promote biliary
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cell differentiation but loose this effect on the C/EBPα deficient or mutated (at Yap
binding residues) hepatoblasts.
This study will identify the Yap-binding transcription factors and its directly
regulating genes in a systematical manner. The results may help to understand the
mechanisms of tumor development driven by Yap activation.
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APPENDIX

Appendix 1. Liver phenotypes of the mutant mice from the rescue experiment. (A) P0,
representative lats1/2 double deleted liver and the wild-type liver of the same
developmental stage. P6, representative alb-cre;lats1/2;taz liver and the wild-type
littermate’s liver. P28, representative alb-cre;lats1/2;yap liver and the wild-type
littermate’s liver. 5 months, representative alb-cre;lats1/2;yap/taz liver and the wild-
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type littermate’s liver. (B) HE staining on liver tissues from the rescue experiment. All
of them show ductal-like expansion. Mice with Lats1/2 and Taz deletions die around
P5-P6 and show the most dramatic ductal hyperplasia. With Lats1/2 and Yaz
deletions, at P11, mutant livers have normal hepatocytes however the liver plates are
disrupted by clumps of unrecognized cells. Livers with Lats1/2 and Yap/Taz deletions
have normal hepatocytes at 2-months age; however there are still clumps of
unrecognized cells penetrating the liver plates.
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Appendix 2. Decreased phospho-Lats1 in Yap/Taz double mutants. During normal
liver regeneration, phosphorylation of Lats1 decreases at 6h and 48h after PH, and
increases at 72h after PH. Total Lats1 gradiently increases in the first three days of
regeneration and returns to normal level at 7d after PH. During Yap/Taz double
mutants’ regeneration, the total Lats1 shows similar pattern as in normal liver;
however, the phosphorylation of Lats1 is significantly decreased.
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Appendix 3. Yap and Taz activities during Mst1/2 double mutants’ regeneration.
Western blot shows that during normal liver regeneration, the phosphorylation of Yap
and Taz are differentially regulated; however they appear to be similarly regulated
during Mst1/2 double mutants’ regeneration. The total protein levels of both Yap and
Taz are increased in Mst1/2 mutant. Actin is used as protein loading controls.

118

BIBILGRAPHY
1. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ (1995) The Drosophila tumor
suppressor gene warts encodes a homolog of human myotonic dystrophy
kinase and is required for the control of cell shape and proliferation. Genes
Dev 9: 534-546.
2. Xu T, Wang W, Zhang S, Stewart RA, Yu W (1995) Identifying tumor suppressors
in genetic mosaics: the Drosophila lats gene encodes a putative protein
kinase. Development 121: 1053-1063.
3. Kango-Singh M, Nolo R, Tao C, Verstreken P, Hiesinger PR, et al. (2002) Shar-pei
mediates cell proliferation arrest during imaginal disc growth in Drosophila.
Development 129: 5719-5730.
4. Harvey KF, Pfleger CM, Hariharan IK (2003) The Drosophila Mst ortholog, hippo,
restricts growth and cell proliferation and promotes apoptosis. Cell 114:
457-467.
5. Pantalacci S, Tapon N, Leopold P (2003) The Salvador partner Hippo promotes
apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 5: 921-927.
6. Jia J, Zhang W, Wang B, Trinko R, Jiang J (2003) The Drosophila Ste20 family
kinase dMST functions as a tumor suppressor by restricting cell
proliferation and promoting apoptosis. Genes Dev 17: 2514-2519.
7. Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G (2003) Hippo promotes
proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell
Biol 5: 914-920.

119

8. Wu S, Huang J, Dong J, Pan D (2003) hippo encodes a Ste-20 family protein
kinase that restricts cell proliferation and promotes apoptosis in conjunction
with salvador and warts. Cell 114: 445-456.
9. Wei X, Shimizu T, Lai ZC (2007) Mob as tumor suppressor is activated by Hippo
kinase for growth inhibition in Drosophila. EMBO J 26: 1772-1781.
10. Glantschnig H, Rodan GA, Reszka AA (2002) Mapping of MST1 kinase sites of
phosphorylation. Activation and autophosphorylation. J Biol Chem 277:
42987-42996.
11. Lee KK, Yonehara S (2002) Phosphorylation and dimerization regulate
nucleocytoplasmic shuttling of mammalian STE20-like kinase (MST). J Biol
Chem 277: 12351-12358.
12. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, et al. (2006) The
tumour-suppressor genes NF2/Merlin and Expanded act through Hippo
signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8: 27-36.
13. Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H The WW domain
protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 18: 309-316.
14. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N Kibra is a regulator of
the Salvador/Warts/Hippo signaling network. Dev Cell 18: 300-308.
15. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, et al. Kibra functions as a tumor
suppressor protein that regulates Hippo signaling in conjunction with Merlin
and Expanded. Dev Cell 18: 288-299.

120

16. Tyler DM, Baker NE (2007) Expanded and fat regulate growth and
differentiation in the Drosophila eye through multiple signaling pathways.
Dev Biol 305: 187-201.
17. Willecke M, Hamaratoglu F, Kango-Singh M, Udan R, Chen CL, et al. (2006) The
fat cadherin acts through the hippo tumor-suppressor pathway to regulate
tissue size. Curr Biol 16: 2090-2100.
18. Silva E, Tsatskis Y, Gardano L, Tapon N, McNeill H (2006) The tumorsuppressor gene fat controls tissue growth upstream of expanded in the
hippo signaling pathway. Curr Biol 16: 2081-2089.
19. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, et al. (2006) Delineation of a Fat
tumor suppressor pathway. Nat Genet 38: 1142-1150.
20. Bennett FC, Harvey KF (2006) Fat cadherin modulates organ size in Drosophila
via the Salvador/Warts/Hippo signaling pathway. Curr Biol 16: 2101-2110.
21. Enomoto M, Igaki T Deciphering tumor-suppressor signaling in flies: genetic
link between Scribble/Dlg/Lgl and the Hippo pathways. J Genet Genomics
38: 461-470.
22. Grusche FA, Richardson HE, Harvey KF Upstream regulation of the hippo size
control pathway. Curr Biol 20: R574-582.
23. Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hippo signaling
pathway coordinately regulates cell proliferation and apoptosis by
inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122: 421-434.
24. Oh H, Irvine KD (2008) In vivo regulation of Yorkie phosphorylation and
localization. Development 135: 1081-1088.

121

25. Oh H, Irvine KD (2009) In vivo analysis of Yorkie phosphorylation sites.
Oncogene 28: 1916-1927.
26. Badouel C, Gardano L, Amin N, Garg A, Rosenfeld R, et al. (2009) The FERMdomain protein Expanded regulates Hippo pathway activity via direct
interactions with the transcriptional activator Yorkie. Dev Cell 16: 411-420.
27. Oh H, Reddy BV, Irvine KD (2009) Phosphorylation-independent repression of
Yorkie in Fat-Hippo signaling. Dev Biol 335: 188-197.
28. Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J, et al. (2008)
SCALLOPED interacts with YORKIE, the nuclear effector of the hippo
tumor-suppressor pathway in Drosophila. Curr Biol 18: 435-441.
29. Zhang L, Ren F, Zhang Q, Chen Y, Wang B, et al. (2008) The TEAD/TEF family of
transcription factor Scalloped mediates Hippo signaling in organ size
control. Dev Cell 14: 377-387.
30. Oh H, Irvine KD Cooperative regulation of growth by Yorkie and Mad through
bantam. Dev Cell 20: 109-122.
31. Peng HW, Slattery M, Mann RS (2009) Transcription factor choice in the Hippo
signaling pathway: homothorax and yorkie regulation of the microRNA
bantam in the progenitor domain of the Drosophila eye imaginal disc. Genes
Dev 23: 2307-2319.
32. Nicolay BN, Bayarmagnai B, Islam AB, Lopez-Bigas N, Frolov MV Cooperation
between dE2F1 and Yki/Sd defines a distinct transcriptional program
necessary to bypass cell cycle exit. Genes Dev 25: 323-335.

122

33. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, et al. (2005)
The Ste20-like kinase Mst2 activates the human large tumor suppressor
kinase Lats1. Oncogene 24: 2076-2086.
34. Dong J, Feldmann G, Huang J, Wu S, Zhang N, et al. (2007) Elucidation of a
universal size-control mechanism in Drosophila and mammals. Cell 130:
1120-1133.
35. Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. (2007) Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact inhibition and
tissue growth control. Genes Dev 21: 2747-2761.
36. Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, et al. (2007) The proapoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors
of Akt1. EMBO J 26: 4523-4534.
37. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, et al. The Hippo-Salvador pathway
restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis.
Proc Natl Acad Sci U S A 107: 8248-8253.
38. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, et al. Hippo signaling is a potent in vivo
growth and tumor suppressor pathway in the mammalian liver. Proc Natl
Acad Sci U S A 107: 1437-1442.
39. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, et al. (2007) Prognostic
significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod
Pathol 20: 331-338.

123

40. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, et al. (2007)
Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol
Carcinog 46: 865-871.
41. Song H, Mak KK, Topol L, Yun K, Hu J, et al. Mammalian Mst1 and Mst2
kinases play essential roles in organ size control and tumor suppression.
Proc Natl Acad Sci U S A 107: 1431-1436.
42. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, et al. (2002) salvador
Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in
human cancer cell lines. Cell 110: 467-478.
43. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, et al. (2006) Promoter hypermethylationmediated down-regulation of LATS1 and LATS2 in human astrocytoma.
Neurosci Res 56: 450-458.
44. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, et al. (2005) Downregulation of LATS1 and LATS2 mRNA expression by promoter
hypermethylation and its association with biologically aggressive phenotype
in human breast cancers. Clin Cancer Res 11: 1380-1385.
45. Kosaka Y, Mimori K, Tanaka F, Inoue H, Watanabe M, et al. (2007) Clinical
significance of the loss of MATS1 mRNA expression in colorectal cancer. Int
J Oncol 31: 333-338.
46. Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, et al. (2005) Control of cell
proliferation and apoptosis by mob as tumor suppressor, mats. Cell 120:
675-685.

124

47. Sasaki H, Kawano O, Endo K, Suzuki E, Yukiue H, et al. (2007) Human MOB1
expression in non-small-cell lung cancer. Clin Lung Cancer 8: 273-276.
48. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, et al. (2008) TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is inhibited by the
hippo pathway. Mol Cell Biol 28: 2426-2436.
49. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, et al. (2006) Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci U S A 103: 12405-12410.
50. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, et al. (2008) Expression
of Yes-associated protein in common solid tumors. Hum Pathol 39: 15821589.
51. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. (2009) Yes-associated protein is
an independent prognostic marker in hepatocellular carcinoma. Cancer 115:
4576-4585.
52. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J (2004) Regulation of the
MST1 kinase by autophosphorylation, by the growth inhibitory proteins,
RASSF1 and NORE1, and by Ras. Biochem J 381: 453-462.
53. Visser S, Yang X LATS tumor suppressor: a new governor of cellular
homeostasis. Cell Cycle 9: 3892-3903.
54. Callus BA, Verhagen AM, Vaux DL (2006) Association of mammalian sterile
twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil
domains, leads to its stabilization and phosphorylation. FEBS J 273: 42644276.

125

55. Polesello C, Huelsmann S, Brown NH, Tapon N (2006) The Drosophila RASSF
homolog antagonizes the hippo pathway. Curr Biol 16: 2459-2465.
56. Zhang N, Bai H, David KK, Dong J, Zheng Y, et al. The Merlin/NF2 tumor
suppressor functions through the YAP oncoprotein to regulate tissue
homeostasis in mammals. Dev Cell 19: 27-38.
57. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, et al. (2000) TAZ: a novel
transcriptional co-activator regulated by interactions with 14-3-3 and PDZ
domain proteins. EMBO J 19: 6778-6791.
58. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML (2001) TEAD/TEF
transcription factors utilize the activation domain of YAP65, a Src/Yesassociated protein localized in the cytoplasm. Genes Dev 15: 1229-1241.
59. Mahoney WM, Jr., Hong JH, Yaffe MB, Farrance IK (2005) The transcriptional
co-activator TAZ interacts differentially with transcriptional enhancer
factor-1 (TEF-1) family members. Biochem J 388: 217-225.
60. Wu S, Liu Y, Zheng Y, Dong J, Pan D (2008) The TEAD/TEF family protein
Scalloped mediates transcriptional output of the Hippo growth-regulatory
pathway. Dev Cell 14: 388-398.
61. Chan SW, Lim CJ, Huang C, Chong YF, Gunaratne HJ, et al. WW domainmediated interaction with Wbp2 is important for the oncogenic property of
TAZ. Oncogene 30: 600-610.
62. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, et al. AXL receptor kinase is a
mediator of YAP-dependent oncogenic functions in hepatocellular
carcinoma. Oncogene 30: 1229-1240.

126

63. Murakami M, Nakagawa M, Olson EN, Nakagawa O (2005) A WW domain
protein TAZ is a critical coactivator for TBX5, a transcription factor
implicated in Holt-Oram syndrome. Proc Natl Acad Sci U S A 102: 1803418039.
64. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, et al. (2008)
TAZ controls Smad nucleocytoplasmic shuttling and regulates human
embryonic stem-cell self-renewal. Nat Cell Biol 10: 837-848.
65. Komuro A, Nagai M, Navin NE, Sudol M (2003) WW domain-containing protein
YAP associates with ErbB-4 and acts as a co-transcriptional activator for the
carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J
Biol Chem 278: 33334-33341.
66. Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, et al. (2002) Yesassociated protein (YAP65) interacts with Smad7 and potentiates its
inhibitory activity against TGF-beta/Smad signaling. Oncogene 21: 48794884.
67. blouin A BR, Weibei ER. (1977) Distribution of organelles and membranes
between hepatocytes and nonhepatocytes in the rat liver parenchyma. A
stereological study. J cell Biol 72: 5.
68. Tremblay KD, Zaret KS (2005) Distinct populations of endoderm cells converge
to generate the embryonic liver bud and ventral foregut tissues. Dev Biol
280: 87-99.
69. Zaret KS, Grompe M (2008) Generation and regeneration of cells of the liver and
pancreas. Science 322: 1490-1494.

127

70. Houssaint E (1980) Differentiation of the mouse hepatic primordium. I. An
analysis of tissue interactions in hepatocyte differentiation. Cell Differ 9:
269-279.
71. Tadei A, Geslin P, Delhumeau A, Victor J, Le Douarin L, et al. (1975)
[Phentolamine in treatment of acute left ventricular insufficiancies]. Arch
Mal Coeur Vaiss 68: 877-885.
72. Medlock ES, Haar JL (1983) The liver hemopoietic environment: I. Developing
hepatocytes and their role in fetal hemopoiesis. Anat Rec 207: 31-41.
73. Giroux S, Charron J (1998) Defective development of the embryonic liver in Nmyc-deficient mice. Dev Biol 195: 16-28.
74. Hentsch B, Lyons I, Li R, Hartley L, Lints TJ, et al. (1996) Hlx homeo box gene
is essential for an inductive tissue interaction that drives expansion of
embryonic liver and gut. Genes Dev 10: 70-79.
75. Porter FD, Drago J, Xu Y, Cheema SS, Wassif C, et al. (1997) Lhx2, a LIM
homeobox gene, is required for eye, forebrain, and definitive erythrocyte
development. Development 124: 2935-2944.
76. Wandzioch E, Kolterud A, Jacobsson M, Friedman SL, Carlsson L (2004) Lhx2-/mice develop liver fibrosis. Proc Natl Acad Sci U S A 101: 16549-16554.
77. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, et al. (2009) Intrahepatic
bile ducts develop according to a new mode of tubulogenesis regulated by
the transcription factor SOX9. Gastroenterology 136: 2325-2333.
78. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der Smissen P,
et al. (2005) Control of liver cell fate decision by a gradient of TGF beta

128

signaling modulated by Onecut transcription factors. Genes Dev 19: 18491854.
79. Clotman F, Lemaigre FP (2006) Control of hepatic differentiation by
activin/TGFbeta signaling. Cell Cycle 5: 168-171.
80. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, et al. (2004) Betacatenin is temporally regulated during normal liver development.
Gastroenterology 126: 1134-1146.
81. Tanimizu N, Miyajima A (2004) Notch signaling controls hepatoblast
differentiation by altering the expression of liver-enriched transcription
factors. J Cell Sci 117: 3165-3174.
82. Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, et al. (2009) Notch signaling
controls liver development by regulating biliary differentiation.
Development 136: 1727-1739.
83. Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, et al. (2009) Notch2
signaling promotes biliary epithelial cell fate specification and tubulogenesis
during bile duct development in mice. Hepatology 50: 871-879.
84. Li L, Krantz ID, Deng Y, Genin A, Banta AB, et al. (1997) Alagille syndrome is
caused by mutations in human Jagged1, which encodes a ligand for Notch1.
Nat Genet 16: 243-251.
85. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, et al. (2006)
NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the
notch signaling pathway. Am J Hum Genet 79: 169-173.

129

86. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, et al. (1997) Mutations in
the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet
16: 235-242.
87. Flynn DM, Nijjar S, Hubscher SG, de Goyet Jde V, Kelly DA, et al. (2004) The
role of Notch receptor expression in bile duct development and disease. J
Pathol 204: 55-64.
88. Kodama Y, Hijikata M, Kageyama R, Shimotohno K, Chiba T (2004) The role of
notch signaling in the development of intrahepatic bile ducts.
Gastroenterology 127: 1775-1786.
89. Loomes KM, Taichman DB, Glover CL, Williams PT, Markowitz JE, et al. (2002)
Characterization of Notch receptor expression in the developing mammalian
heart and liver. Am J Med Genet 112: 181-189.
90. Louis AA, Van Eyken P, Haber BA, Hicks C, Weinmaster G, et al. (1999) Hepatic
jagged1 expression studies. Hepatology 30: 1269-1275.
91. McCright B, Lozier J, Gridley T (2002) A mouse model of Alagille syndrome:
Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129:
1075-1082.
92. Moreira RK (2007) Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med
131: 1728-1734.
93. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer
burden: Globocan 2000. Int J Cancer 94: 153-156.
94. Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and
treatment. Gastroenterology 122: 1609-1619.

130

95. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma.
Hepatology 42: 1208-1236.
96. Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY (2004) Surgery for
hepatocellular carcinoma: does it improve survival? Ann Surg Oncol 11: 298303.
97. Beasley RP (1988) Hepatitis B virus. The major etiology of hepatocellular
carcinoma. Cancer 61: 1942-1956.
98. Roskams T (2006) Liver stem cells and their implication in hepatocellular and
cholangiocarcinoma. Oncogene 25: 3818-3822.
99. Magee JA, Piskounova E, Morrison SJ Cancer stem cells: impact, heterogeneity,
and uncertainty. Cancer Cell 21: 283-296.
100. Sell S, Leffert HL (2008) Liver cancer stem cells. J Clin Oncol 26: 2800-2805.
101. Dan YY, Yeoh GC (2008) Liver stem cells: a scientific and clinical perspective.
J Gastroenterol Hepatol 23: 687-698.
102. Sell S (1997) Electron microscopic identification of putative liver stem cells
and intermediate hepatocytes following periportal necrosis induced in rats
by allyl alcohol. Stem Cells 15: 378-385.
103. Dorrell C, Erker L, Lanxon-Cookson KM, Abraham SL, Victoroff T, et al. (2008)
Surface markers for the murine oval cell response. Hepatology 48: 12821291.
104. Conlon I, Raff M (1999) Size control in animal development. Cell 96: 235-244.
105. Raff MC (1996) Size control: the regulation of cell numbers in animal
development. Cell 86: 173-175.

131

106. Prout T, Barker JS (1989) Ecological aspects of the heritability of body size in
Drosophila buzzatii. Genetics 123: 803-813.
107. Fankhauser G (1952) Nucleo-cytoplasmic relations in amphibian development.
INt Rev Cytol 1: 29.
108. Neufeld TP, de la Cruz AF, Johnston LA, Edgar BA (1998) Coordination of
growth and cell division in the Drosophila wing. Cell 93: 1183-1193.
109. Weigmann K, Cohen SM, Lehner CF (1997) Cell cycle progression, growth and
patterning in imaginal discs despite inhibition of cell division after
inactivation of Drosophila Cdc2 kinase. Development 124: 3555-3563.
110. Weinkove D, Leevers SJ (2000) The genetic control of organ growth: insights
from Drosophila. Curr Opin Genet Dev 10: 75-80.
111. Schmidt EE, Schibler U (1995) Cell size regulation, a mechanism that controls
cellular RNA accumulation: consequences on regulation of the ubiquitous
transcription factors Oct1 and NF-Y and the liver-enriched transcription
factor DBP. J Cell Biol 128: 467-483.
112. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, et al. (2000) The
conserved phosphoinositide 3-kinase pathway determines heart size in mice.
EMBO J 19: 2537-2548.
113. Mullany LK, Nelsen CJ, Hanse EA, Goggin MM, Anttila CK, et al. (2007) Aktmediated liver growth promotes induction of cyclin E through a novel
translational mechanism and a p21-mediated cell cycle arrest. J Biol Chem
282: 21244-21252.

132

114. Haga S, Ogawa W, Inoue H, Terui K, Ogino T, et al. (2005) Compensatory
recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liverspecific STAT3-deficient mice. J Hepatol 43: 799-807.
115. Haga S, Ozaki M, Inoue H, Okamoto Y, Ogawa W, et al. (2009) The survival
pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent
protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte
size rather than proliferation. Hepatology 49: 204-214.
116. Pan D (2007) Hippo signaling in organ size control. Genes Dev 21: 886-897.
117. Huang H, Potter CJ, Tao W, Li DM, Brogiolo W, et al. (1999) PTEN affects cell
size, cell proliferation and apoptosis during Drosophila eye development.
Development 126: 5365-5372.
118. Goberdhan DC, Paricio N, Goodman EC, Mlodzik M, Wilson C (1999)
Drosophila tumor suppressor PTEN controls cell size and number by
antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev 13: 32443258.
119. Gao X, Neufeld TP, Pan D (2000) Drosophila PTEN regulates cell growth and
proliferation through PI3K-dependent and -independent pathways. Dev Biol
221: 404-418.
120. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN
suppresses tumor formation by restraining the phosphoinositide 3kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245.
121. Borkowska J, Schwartz RA, Kotulska K, Jozwiak S Tuberous sclerosis
complex: tumors and tumorigenesis. Int J Dermatol 50: 13-20.

133

122. Potter CJ, Pedraza LG, Huang H, Xu T (2003) The tuberous sclerosis complex
(TSC) pathway and mechanism of size control. Biochem Soc Trans 31: 584586.
123. Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276: 6066.
124. Higgins GM AR (1931) Experimental pathology of the liver, 1:Restoration of
the liver of the white rat following partial surgical removal. Arch Pathol: 7.
125. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, et al. (2003) Control
mechanism of the circadian clock for timing of cell division in vivo. Science
302: 255-259.
126. Schibler U (2003) Circadian rhythms. Liver regeneration clocks on. Science
302: 234-235.
127. Ehrenfried JA, Ko TC, Thompson EA, Evers BM (1997) Cell cycle-mediated
regulation of hepatic regeneration. Surgery 122: 927-935.
128. Mohammed FF, Khokha R (2005) Thinking outside the cell: proteases regulate
hepatocyte division. Trends Cell Biol 15: 555-563.
129. Su AI, Guidotti LG, Pezacki JP, Chisari FV, Schultz PG (2002) Gene expression
during the priming phase of liver regeneration after partial hepatectomy in
mice. Proc Natl Acad Sci U S A 99: 11181-11186.
130. White P, Brestelli JE, Kaestner KH, Greenbaum LE (2005) Identification of
transcriptional networks during liver regeneration. J Biol Chem 280: 37153722.

134

131. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, et al.
(1996) Liver failure and defective hepatocyte regeneration in interleukin-6deficient mice. Science 274: 1379-1383.
132. Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH (2001)
Transient expression of cyclin D1 is sufficient to promote hepatocyte
replication and liver growth in vivo. Cancer Res 61: 8564-8568.
133. Albrecht JH, Hansen LK (1999) Cyclin D1 promotes mitogen-independent cell
cycle progression in hepatocytes. Cell Growth Differ 10: 397-404.
134. Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, et al. (2006)
Hepatocyte proliferation during liver regeneration is impaired in mice with
liver-specific IGF-1R knockout. Faseb J 20: 773-775.
135. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a
universal inhibitor of cyclin kinases. Nature 366: 701-704.
136. Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, et al. (2006) c-Jun/AP-1
controls liver regeneration by repressing p53/p21 and p38 MAPK activity.
Genes Dev 20: 2306-2314.
137. Lutz W, Leon J, Eilers M (2002) Contributions of Myc to tumorigenesis.
Biochim Biophys Acta 1602: 61-71.
138. Dang CV MYC on the path to cancer. Cell 149: 22-35.
139. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, et al. (1989)
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
Science 244: 217-221.
140. Koshland DE, Jr. (1993) Molecule of the year. Science 262: 1953.

135

141. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, et al. (2008) A role for TAZ in
migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68:
2592-2598.
142. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, et al. TAZ is a novel oncogene in
non-small cell lung cancer. Oncogene 30: 2181-2186.
143. Jimenez-Velasco A, Roman-Gomez J, Agirre X, Barrios M, Navarro G, et al.
(2005) Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is
associated with poor prognosis in acute lymphoblastic leukemia. Leukemia
19: 2347-2350.
144. Hisaoka M, Tanaka A, Hashimoto H (2002) Molecular alterations of hwarts/LATS1 tumor suppressor in human soft tissue sarcoma. Lab Invest 82:
1427-1435.
145. Strazisar M, Mlakar V, Glavac D (2009) LATS2 tumour specific mutations and
down-regulation of the gene in non-small cell carcinoma. Lung Cancer 64:
257-262.
146. Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, et al.
(2004) The LATS2/KPM tumor suppressor is a negative regulator of the
androgen receptor. Mol Endocrinol 18: 2011-2023.
147. Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, et al. (2008) Multiple
renal cysts, urinary concentration defects, and pulmonary emphysematous
changes in mice lacking TAZ. Am J Physiol Renal Physiol 294: F542-553.

136

148. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, et al. The Hippo
transducer TAZ confers cancer stem cell-related traits on breast cancer cells.
Cell 147: 759-772.
149. Oh S, Lee D, Kim T, Kim TS, Oh HJ, et al. (2009) Crucial role for Mst1 and
Mst2 kinases in early embryonic development of the mouse. Mol Cell Biol
29: 6309-6320.
150. Lee JH, Kim TS, Yang TH, Koo BK, Oh SP, et al. (2008) A crucial role of WW45
in developing epithelial tissues in the mouse. EMBO J 27: 1231-1242.
151. St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, et al. (1999) Mice
deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and
pituitary dysfunction. Nat Genet 21: 182-186.
152. Yabuta N, Okada N, Ito A, Hosomi T, Nishihara S, et al. (2007) Lats2 is an
essential mitotic regulator required for the coordination of cell division. J
Biol Chem 282: 19259-19271.
153. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, et al.
(2006) Defects in yolk sac vasculogenesis, chorioallantoic fusion, and
embryonic axis elongation in mice with targeted disruption of Yap65. Mol
Cell Biol 26: 77-87.
154. Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, et al. (2007) Glomerulocystic kidney
disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U
S A 104: 1631-1636.
155. Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, et al. (2009) The Hippo
signaling pathway components Lats and Yap pattern Tead4 activity to

137

distinguish mouse trophectoderm from inner cell mass. Dev Cell 16: 398410.
156. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, et al. (1997) Cremediated gene deletion in the mammary gland. Nucleic Acids Res 25: 43234330.
157. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, et al. (2006) A novel
somatic mouse model to survey tumorigenic potential applied to the
Hedgehog pathway. Cancer Res 66: 10171-10178.
158. Postic C, Magnuson MA (2000) DNA excision in liver by an albumin-Cre
transgene occurs progressively with age. Genesis 26: 149-150.
159. Shiojiri N (1981) Enzymo- and immunocytochemical analyses of the
differentiation of liver cells in the prenatal mouse. J Embryol Exp Morphol
62: 139-152.
160. Wang ND, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, et al. (1995)
Impaired energy homeostasis in C/EBP alpha knockout mice. Science 269:
1108-1112.
161. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, et al. Hippo
pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and
heart size. Science 332: 458-461.
162. Pistoi S, Morello D (1996) Liver regeneration 7. Prometheus' myth revisited:
transgenic mice as a powerful tool to study liver regeneration. FASEB J 10:
819-828.

138

163. Sanders JA, Schorl C, Patel A, Sedivy JM, Gruppuso PA Postnatal liver growth
and regeneration are independent of c-myc in a mouse model of conditional
hepatic c-myc deletion. BMC Physiol 12: 1.
164. Li F, Xiang Y, Potter J, Dinavahi R, Dang CV, et al. (2006) Conditional deletion
of c-myc does not impair liver regeneration. Cancer Res 66: 5608-5612.
165. Mitchell C, Willenbring H (2008) A reproducible and well-tolerated method for
2/3 partial hepatectomy in mice. Nat Protoc 3: 1167-1170.
166. Fausto N, Campbell JS, Riehle KJ (2006) Liver regeneration. Hepatology 43:
S45-53.
167. Zerrad-Saadi A, Lambert-Blot M, Mitchell C, Bretes H, Collin de l'Hortet A, et
al. GH receptor plays a major role in liver regeneration through the control
of EGFR and ERK1/2 activation. Endocrinology 152: 2731-2741.
168. Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell
Biol 5: 836-847.
169. Malumbres M, Mangues R, Ferrer N, Lu S, Pellicer A (1997) Isolation of high
molecular weight DNA for reliable genotyping of transgenic mice.
Biotechniques 22: 1114-1119.
170. Attal J, Cajero-Juarez M, Houdebine LM (1995) A simple method of DNA
extraction from whole tissues and blood using glass powder for detection of
transgenic animals by PCR. Transgenic Res 4: 149-150.
171. Lin CS, Magnuson T, Samols D (1989) A rapid procedure to identify newborn
transgenic mice. DNA 8: 297-299.

139

172. Cantz T, Manns MP, Ott M (2008) Stem cells in liver regeneration and therapy.
Cell Tissue Res 331: 271-282.
173. Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, et al. (2009) New
insights into liver stem cells. Dig Liver Dis 41: 455-462.
174. Crosby HA, Hubscher SG, Joplin RE, Kelly DA, Strain AJ (1998)
Immunolocalization of OV-6, a putative progenitor cell marker in human
fetal and diseased pediatric liver. Hepatology 28: 980-985.
175. Crosby HA, Hubscher S, Fabris L, Joplin R, Sell S, et al. (1998)
Immunolocalization of putative human liver progenitor cells in livers from
patients with end-stage primary biliary cirrhosis and sclerosing cholangitis
using the monoclonal antibody OV-6. Am J Pathol 152: 771-779.
176. Engelhardt NV, Factor VM, Medvinsky AL, Baranov VN, Lazareva MN, et al.
(1993) Common antigen of oval and biliary epithelial cells (A6) is a
differentiation marker of epithelial and erythroid cell lineages in early
development of the mouse. Differentiation 55: 19-26.
177. Factor VM, Radaeva SA (1993) Oval cells--hepatocytes relationships in Dipininduced hepatocarcinogenesis in mice. Exp Toxicol Pathol 45: 239-244.
178. Lemaigre FP (2003) Development of the biliary tract. Mech Dev 120: 81-87.
179. Raynaud P, Carpentier R, Antoniou A, Lemaigre FP Biliary differentiation and
bile duct morphogenesis in development and disease. Int J Biochem Cell Biol
43: 245-256.
180. Michalopoulos GK (2007) Liver regeneration. J Cell Physiol 213: 286-300.

140

181. Espeillac C, Mitchell C, Celton-Morizur S, Chauvin C, Koka V, et al. S6 kinase 1
is required for rapamycin-sensitive liver proliferation after mouse
hepatectomy. J Clin Invest 121: 2821-2832.
182. Liao Y, Shikapwashya ON, Shteyer E, Dieckgraefe BK, Hruz PW, et al. (2004)
Delayed hepatocellular mitotic progression and impaired liver regeneration
in early growth response-1-deficient mice. J Biol Chem 279: 43107-43116.
183. Li W, Liang X, Kellendonk C, Poli V, Taub R (2002) STAT3 contributes to the
mitogenic response of hepatocytes during liver regeneration. J Biol Chem
277: 28411-28417.
184. Ahn SH, Cheung WL, Hsu JY, Diaz RL, Smith MM, et al. (2005) Sterile 20
kinase phosphorylates histone H2B at serine 10 during hydrogen peroxideinduced apoptosis in S. cerevisiae. Cell 120: 25-36.
185. Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA (2001) Both
phosphorylation and caspase-mediated cleavage contribute to regulation of
the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J
Biol Chem 276: 14909-14915.
186. Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S (2001) MST, a
physiological caspase substrate, highly sensitizes apoptosis both upstream
and downstream of caspase activation. J Biol Chem 276: 19276-19285.
187. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, et al. (2006) Role of the tumor
suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 66: 2562-2569.

141

188. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, et al. (2002)
Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 12:
253-265.
189. Zhou D, Conrad C, Xia F, Park JS, Payer B, et al. (2009) Mst1 and Mst2
maintain hepatocyte quiescence and suppress hepatocellular carcinoma
development through inactivation of the Yap1 oncogene. Cancer Cell 16:
425-438.
190. Katagiri K, Imamura M, Kinashi T (2006) Spatiotemporal regulation of the
kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and
adhesion. Nat Immunol 7: 919-928.
191. Zhou D, Medoff BD, Chen L, Li L, Zhang XF, et al. (2008) The Nore1B/Mst1
complex restrains antigen receptor-induced proliferation of naive T cells.
Proc Natl Acad Sci U S A 105: 20321-20326.
192. Seki S, Nakashima H, Nakashima M, Kinoshita M Antitumor immunity
produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T
cells. Clin Dev Immunol 2011: 868345.
193. Gale RP (1987) Development of the immune system in human fetal liver.
Thymus 10: 45-56.
194. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, et al. (2009)
Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 1155:
206-221.
195. Karin M (2006) Nuclear factor-kappaB in cancer development and progression.
Nature 441: 431-436.

142

196. Sharma S, Kelly TK, Jones PA Epigenetics in cancer. Carcinogenesis 31: 27-36.
197. Wen W, Zhu F, Zhang J, Keum YS, Zykova T, et al. MST1 promotes apoptosis
through phosphorylation of histone H2AX. J Biol Chem 285: 39108-39116.
198. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, et al. (2003) Apoptotic
phosphorylation of histone H2B is mediated by mammalian sterile twenty
kinase. Cell 113: 507-517.
199. Watabe M, Kakeya H, Onose R, Osada H (2000) Activation of MST/Krs and cJun N-terminal kinases by different signaling pathways during cytotrienin
A-induced apoptosis. J Biol Chem 275: 8766-8771.
200. Lowndes NF, Toh GW (2005) DNA repair: the importance of phosphorylating
histone H2AX. Curr Biol 15: R99-R102.
201. Pinto DM, Flaus A Structure and function of histone H2AX. Subcell Biochem
50: 55-78.
202. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, et al.
(2002) Genomic instability in mice lacking histone H2AX. Science 296: 922927.
203. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, et al. gammaH2AX
foci analysis for monitoring DNA double-strand break repair: strengths,
limitations and optimization. Cell Cycle 9: 662-669.
204. Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples
hepatocyte death to cytokine-driven compensatory proliferation that
promotes chemical hepatocarcinogenesis. Cell 121: 977-990.

143

205. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, et al. (2008) Hepatocyte
necrosis induced by oxidative stress and IL-1 alpha release mediate
carcinogen-induced compensatory proliferation and liver tumorigenesis.
Cancer Cell 14: 156-165.
206. Visser S, Yang X Identification of LATS transcriptional targets in HeLa cells
using whole human genome oligonucleotide microarray. Gene 449: 22-29.
207. Suzuki A, Sekiya S, Buscher D, Izpisua Belmonte JC, Taniguchi H (2008) Tbx3
controls the fate of hepatic progenitor cells in liver development by
suppressing p19ARF expression. Development 135: 1589-1595.
208. Alagille D, Odievre M, Gautier M, Dommergues JP (1975) Hepatic ductular
hypoplasia associated with characteristic facies, vertebral malformations,
retarded physical, mental, and sexual development, and cardiac murmur. J
Pediatr 86: 63-71.
209. Record CJ, Chaikuad A, Rellos P, Das S, Pike AC, et al. Structural comparison
of human mammalian ste20-like kinases. PLoS One 5: e11905.
210. Stegert MR, Hergovich A, Tamaskovic R, Bichsel SJ, Hemmings BA (2005)
Regulation of NDR protein kinase by hydrophobic motif phosphorylation
mediated by the mammalian Ste20-like kinase MST3. Mol Cell Biol 25:
11019-11029.
211. Potter CJ, Xu T (2001) Mechanisms of size control. Curr Opin Genet Dev 11:
279-286.
212. Thomas G, Hall MN (1997) TOR signalling and control of cell growth. Curr
Opin Cell Biol 9: 782-787.

144

213. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:
253-262.
214. Jackson LN, Larson SD, Silva SR, Rychahou PG, Chen LA, et al. (2008)
PI3K/Akt activation is critical for early hepatic regeneration after partial
hepatectomy. Am J Physiol Gastrointest Liver Physiol 294: G1401-1410.
215. Natarajan A, Wagner B, Sibilia M (2007) The EGF receptor is required for
efficient liver regeneration. Proc Natl Acad Sci U S A 104: 17081-17086.
216. Wustefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C (2000)
Hyperstimulation with interleukin 6 inhibits cell cycle progression after
hepatectomy in mice. Hepatology 32: 514-522.
217. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, et al. (2009)
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation
of mTORC1 is associated with meningioma and schwannoma growth. Mol
Cell Biol 29: 4250-4261.
218. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG (2009) Loss of
the tumor suppressor gene NF2, encoding merlin, constitutively activates
integrin-dependent mTORC1 signaling. Mol Cell Biol 29: 4235-4249.
219. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, et al. (2006) A conserved
MST-FOXO signaling pathway mediates oxidative-stress responses and
extends life span. Cell 125: 987-1001.
220. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, et al. Regulation of insulinlike growth factor signaling by Yap governs cardiomyocyte proliferation and
embryonic heart size. Sci Signal 4: ra70.

145

221. Ziosi M, Baena-Lopez LA, Grifoni D, Froldi F, Pession A, et al. dMyc functions
downstream of Yorkie to promote the supercompetitive behavior of hippo
pathway mutant cells. PLoS Genet 6.
222. Neto-Silva RM, de Beco S, Johnston LA Evidence for a growth-stabilizing
regulatory feedback mechanism between Myc and Yorkie, the Drosophila
homolog of Yap. Dev Cell 19: 507-520.
223. Ravitz MJ, Chen L, Lynch M, Schmidt EV (2007) c-myc Repression of TSC2
contributes to control of translation initiation and Myc-induced
transformation. Cancer Res 67: 11209-11217.
224. Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M (1997) Role of
the tuberous sclerosis gene-2 product in cell cycle control. Loss of the
tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol
Chem 272: 29301-29308.
225. Soucek T, Rosner M, Miloloza A, Kubista M, Cheadle JP, et al. (2001) Tuberous
sclerosis causing mutants of the TSC2 gene product affect proliferation and
p27 expression. Oncogene 20: 4904-4909.
226. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E (2000) Genetic and
biochemical characterization of dTOR, the Drosophila homolog of the target
of rapamycin. Genes Dev 14: 2689-2694.
227. Volarevic S, Stewart MJ, Ledermann B, Zilberman F, Terracciano L, et al.
(2000) Proliferation, but not growth, blocked by conditional deletion of 40S
ribosomal protein S6. Science 288: 2045-2047.

146

228. Jiang YP, Ballou LM, Lin RZ (2001) Rapamycin-insensitive regulation of 4eBP1 in regenerating rat liver. J Biol Chem 276: 10943-10951.
229. Goggin MM, Nelsen CJ, Kimball SR, Jefferson LS, Morley SJ, et al. (2004)
Rapamycin-sensitive induction of eukaryotic initiation factor 4F in
regenerating mouse liver. Hepatology 40: 537-544.
230. Basu S, Totty NF, Irwin MS, Sudol M, Downward J (2003) Akt phosphorylates
the Yes-associated protein, YAP, to induce interaction with 14-3-3 and
attenuation of p73-mediated apoptosis. Mol Cell 11: 11-23.
231. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the
PI3K/Akt/mTOR pathway: effective combinations and clinical
considerations. Drug Resist Updat 11: 32-50.
232. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, et al.
(2005) Akt activates the mammalian target of rapamycin by regulating
cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089.
233. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y (1999) A WW domaincontaining yes-associated protein (YAP) is a novel transcriptional coactivator. EMBO J 18: 2551-2562.
234. Hu S, Xie Z, Qian J, Blackshaw S, Zhu H (2010) Functional protein microarray
technology. Wiley Interdiscip Rev Syst Biol Med 3: 255-268.
235. Tomizawa M, Garfield S, Factor V, Xanthopoulos KG (1998) Hepatocytes
deficient in CCAAT/enhancer binding protein alpha (C/EBP alpha) exhibit
both hepatocyte and biliary epithelial cell character. Biochem Biophys Res
Commun 249: 1-5.

147

236. Shiojiri N, Takeshita K, Yamasaki H, Iwata T (2004) Suppression of C/EBP
alpha expression in biliary cell differentiation from hepatoblasts during
mouse liver development. J Hepatol 41: 790-798.
237. Yamasaki H, Sada A, Iwata T, Niwa T, Tomizawa M, et al. (2006) Suppression
of C/EBPalpha expression in periportal hepatoblasts may stimulate biliary
cell differentiation through increased Hnf6 and Hnf1b expression.
Development 133: 4233-4243.
238. Yoshida Y, Hughes DE, Rausa FM, 3rd, Kim IM, Tan Y, et al. (2006)
C/EBPalpha and HNF6 protein complex formation stimulates HNF6dependent transcription by CBP coactivator recruitment in HepG2 cells.
Hepatology 43: 276-286.
239. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, et al. (1989) Tissuespecific expression, developmental regulation, and genetic mapping of the
gene encoding CCAAT/enhancer binding protein. Genes Dev 3: 1146-1156.
240. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL (1988)
Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev 2:
786-800.
241. Antonson P, Xanthopoulos KG (1995) Molecular cloning, sequence, and
expression patterns of the human gene encoding CCAAT/enhancer binding
protein alpha (C/EBP alpha). Biochem Biophys Res Commun 215: 106-113.
242. Friedman AD, Landschulz WH, McKnight SL (1989) CCAAT/enhancer binding
protein activates the promoter of the serum albumin gene in cultured
hepatoma cells. Genes Dev 3: 1314-1322.

148

243. Dinic S, Bogojevic D, Petrovic M, Poznanovic G, Ivanovic-Matic S, et al. (2005)
C/EBP alpha and C/EBP beta regulate haptoglobin gene expression during rat
liver development and the acute-phase response. Mol Biol Rep 32: 141-147.
244. Park EA, Roesler WJ, Liu J, Klemm DJ, Gurney AL, et al. (1990) The role of the
CCAAT/enhancer-binding protein in the transcriptional regulation of the
gene for phosphoenolpyruvate carboxykinase (GTP). Mol Cell Biol 10: 62646272.
245. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, et al. (2002) The
onecut transcription factor HNF6 is required for normal development of the
biliary tract. Development 129: 1819-1828.
246. Coffinier C, Gresh L, Fiette L, Tronche F, Schutz G, et al. (2002) Bile system
morphogenesis defects and liver dysfunction upon targeted deletion of
HNF1beta. Development 129: 1829-1838.
247. Shen CN, Slack JM, Tosh D (2000) Molecular basis of transdifferentiation of
pancreas to liver. Nat Cell Biol 2: 879-887.
248. Kinoshita T, Sekiguchi T, Xu MJ, Ito Y, Kamiya A, et al. (1999) Hepatic
differentiation induced by oncostatin M attenuates fetal liver hematopoiesis.
Proc Natl Acad Sci U S A 96: 7265-7270.
249. Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, et al. (1999) Fetal liver
development requires a paracrine action of oncostatin M through the gp130
signal transducer. EMBO J 18: 2127-2136.

149

250. Yoshimura A, Ichihara M, Kinjyo I, Moriyama M, Copeland NG, et al. (1996)
Mouse oncostatin M: an immediate early gene induced by multiple cytokines
through the JAK-STAT5 pathway. EMBO J 15: 1055-1063.

150

VITA

Li Lu was born in Taicang, Jiangsu, China in 1977. After completing her work at
Shaxi High School, Taicang, Jiangsu in 1996, she entered Nanjing University in
Nanjing, Jiangsu. She received the degree of Bachelor of Science with a major in
Biology from Nanjing University in July 2000. For the next two years, she worked as a
research technician in the Institution of Molecular Medicine at Nanjing University. In
September of 2002, she entered Nanjing Medical University in Nanjing. She received
the degree of Master of Science with a major in Biomedical Science from Nanjing
Medical University in July 2005. For the next two years, she worked as a research
assistant in the Department of Neuron-Oncology at MD Anderson Cancer Center. In
August of 2007 she entered the University of Texas Health Science Center at Houston
Graduate School of Biomedical Sciences.

Permanent address:
Fuqiao Peace Gordon 35-404,
Taicang, Jiangsu, 215434
P.R.China

151

